Document:

EX-10.14

 Exhibit 10.14 

 

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and
(ii) would be competitively harmful if publicly disclosed. 

 EXCLUSIVE LICENSE AGREEMENT 

between 
 THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA 
 and 

TheRas, Inc. 
 for 

Covalent Modification on CAAX- box Cysteine of K-Ras 4B Using Tethering Compounds 

UC Case No. [***] 

 TABLE OF CONTENTS 
  

							
	Article No.	 	Title	  	Page	 
	 BACKGROUND
	  	 	1	 
	 1.
	 	 DEFINITIONS
	  	 	2	 
	 2.
	 	 GRANT
	  	 	6	 
	 3.
	 	 SUBLICENSES
	  	 	7	 
	 4.
	 	 OPTION
	  	 	9	 
	 5.
	 	 PAYMENT TERMS
	  	 	11	 
	 6.
	 	 LICENSE ISSUE FEE
	  	 	12	 
	 7.
	 	 LICENSE MAINTENANCE FEE
	  	 	12	 
	 8.
	 	 PAYMENTS ON SUBLICENSES
	  	 	13	 
	 9.
	 	 EARNED ROYALTIES AND MINIMUM ANNUAL ROYALTIES
	  	 	13	 
	 10.
	 	 MILESTONE PAYMENTS
	  	 	14	 
	 11.
	 	 INDEXED MILESTONE
	  	 	15	 
	 12.
	 	 PARTICIPATION RIGHTS
	  	 	17	 
	 13.
	 	 DUE DILIGENCE
	  	 	17	 
	 14.
	 	 PROGRESS AND ROYALTY REPORTS
	  	 	19	 
	 15.
	 	 BOOKS AND RECORDS
	  	 	20	 
	 16.
	 	 LIFE OF THE AGREEMENT
	  	 	20	 
	 17.
	 	 TERMINATION
	  	 	21	 
	 18.
	 	 USE OE NAMES AND TRADEMARKS
	  	 	22	 
	 19.
	 	 LIMITED WARRANTY
	  	 	23	 
	 20.
	 	 LIMITATION OF LIABILITY
	  	 	24	 
	 21.
	 	 PATENT PROSECUTION AND MAINTENANCE
	  	 	25	 
	 22.
	 	 PATENT MARKING
	  	 	26	 
	 23.
	 	 PATENT INFRINGEMENT
	  	 	26	 
	 24.
	 	 INDEMNIFICATION
	  	 	29	 
	 25.
	 	 NOTICES
	  	 	31	 
	 26.
	 	 ASSIGNABILITY
	  	 	32	 
	 27.
	 	 FORCE MAJEURE
	  	 	32	 
	 28.
	 	 GOVERNING LAWS; VENUE
	  	 	32	 
	 29.
	 	 GOVERNMENT APPROVAL OR REGISTRATION
	  	 	33	 
	 30.
	 	 COMPLIANCE WITH LAWS
	  	 	33	 
	 31.
	 	 CONFIDENTIALITY
	  	 	33	 
	 32.
	 	 MISCELLANEOUS
	  	 	35	 
	 APPENDIX A: CONSENT TO SUBSTITUTION OF PARTY
	  	 	38	 

 EXECUTION COPY 

CONFIDENTIAL 
 UC Case
No(s).        [***] 
 EXCLUSIVE LICENSE AGREEMENT 

for 
 Covalent
Modification on CAAX- box Cysteine of K-Ras 4B Using Tethering Compounds 
 This exclusive
license agreement (“Agreement”) is made effective this 28th day of September, 2016 (“Effective Date”), by and between The Regents of the University of California, a California public corporation, having its statewide
administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 (“The Regents”) and acting through its Office of Innovation, Technology, and Alliances, University of California San Francisco (“UCSF”),
3333 California Street, Suite S-11, San Francisco, CA 94143 and TheRas, Inc., a Delaware corporation, having a principal place of business at 165 University Avenue, Suite 5, Palo Alto, CA 94301
(“Licensee”) and a subsidiary of BridgeBio, LLC. 
 BACKGROUND 

A.     Certain inventions, generally characterized as “Covalent Modification on
CAAX-box Cysteine of K-Ras 4B Using Tethering Compounds” ([***]) (collectively “Invention”), made in the course of research at UCSF and Leidos Biomedical
Research, Inc. (“Leidos”) by Drs. Frank P. McCormick, Stephan C. Gysin, Adam R. Renslo, and David Turner at UCSF and by Drs. Anna E. Maciag and Oleg Chertov of Leidos (collectively, the “Inventors”) and are claimed in Patent
Rights as defined below. 
 B.    The development of the Invention was sponsored in part by the National Institutes of
Health and, as a consequence, this license is subject to overriding obligations to the United States Federal Government under 35 U.S.C. §§ 200-212 and applicable regulations including a nonexclusive,
non-transferable, irrevocable, paid-up license to practice or have practiced the Invention for or on behalf of the United States Government throughout the world. 

C.     The Regents and Leidos have executed an Inter-Institutional Agreement (UC Control No. 2017-18-0104 ) with an effective date of August 22, 2016, which grants The Regents the right to license the Invention on behalf of both parties (the “IIA”). 

D.    The Licensee and The Regents have executed a Secrecy Agreement (UC Control No. 2016-20-0326) with an effective date of February 28, 2016. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 1 

 E.    The scope of such rights granted by The Regents is intended to
extend to the scope of the patents and patent applications in Patent Rights, but only to the extent that The Regents has proprietary rights in and to the Valid Claims of such Patent Rights. 

F.    Both parties recognize and agree that Earned Royalties are due under this Agreement with respect to products,
services and methods and that such royalties will be paid with respect to both pending patent applications and issued patents, in accordance with the terms and conditions set forth herein, 

G.     The Licensee is a “small business firm” as defined in 15 U.S.C. §632. 

- - oo 0 oo - - 
 The parties
agree as follows: 
 1. DEFINITIONS 

As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings: 

 

	1.1	 “Affiliate” of the Licensee means any entity which, directly or indirectly, Controls the Licensee, is
Controlled by the Licensee or is under common Control with the Licensee. “Control” means (i) having the actual, present capacity to elect a majority of the directors of the applicable entity; (ii) having the power
to direct at least fifty percent (50%) of the voting rights entitled to elect directors of the applicable entity; or (iii) in any country where the local law will not permit foreign equity participation of a majority, ownership or
control, directly or indirectly, of the maximum percentage of such outstanding stock or voting rights permitted by local law. 

  

	1.2	 “Combination Product” means a product that in a single formulation or in a single package contains
both a compound that is a Licensed Product and one or more Combination Product Component(s), provided that (i) such Combination Product Component and such Licensed Product are capable of being Sold (but may not be actually Sold) either
separately from such combined product, with or without other therapeutic products by the Licensee or any Affiliate, or Sublicensee or the patent holder of the Combination Product Component and (ii) the market price of such combined

  
 2 

	 	
product is higher than the market price for such Licensed Product (or what should have been if such Licensed Product is not Sold separately) as a result of such combined product containing or
using such Combination Product Component. 

  

	1.3	 “Combination Product Component” means [***]. 

 

	1.4	 “Field of Use” means prophylactic and therapeutic uses in humans. 

 

	1.5	 “Licensed Method” means any process, art or method the use or practice of which, but for the license
granted in this Agreement, would infringe, or contribute to, or induce the infringement of, any Patent Rights in any country were they issued at the time of the infringing activity in that country. 

 

	1.6	 “Licensed Product(s)” means any product, including, without limitation, a product for use or used in
practicing a Licensed Method and any product made by practicing a Licensed Method, the manufacture, use, Sale, offer for Sale or import of which, but for the license granted in this Agreement, would infringe, or contribute to, or induce the
infringement of, any Patent Rights in any country were they issued at the time of the infringing activity in that country. 

  

	1.7	 “Licensed Service(s)” means any service provided for consideration (whether in cash or any other
form), when such service (i) involves the use of a Licensed Product or (ii) involves the practice of a Licensed Method. 

  

	1.8	 “Method of Use Licensed Product” means any Licensed Product or Licensed Service, the method of use of
which is claimed by at least one Valid Claim included in the Patent Rights and is not a Therapeutic Licensed Product. 

  

	1.9	 “Net Sale” means [***]. 

[***] 
 Notwithstanding the
foregoing, transfers or other dispositions of Licensed Products for [***]. Licensee shall include in its progress reports submitted pursuant to Paragraph 14.1 a description of all Sales occurring in the relevant reporting period that it believes are
within the scope of this paragraph. If it is unclear to The Regents that a transfer or other disposition of Licensed Products falls within the scope of this paragraph, the parties will promptly confer and attempt to resolve the matter in good faith.

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 3 

	1.10	 “Option Invention” means inventions which (i) constitute patentable advancements,
developments or improvements to the Invention, whether or not the subject of any patent application, which are not sufficiently supported by the specification of a previously-filed patent or patent application within the Patent Rights to be entitled
to the priority date of the previously-filed patent or patent application; (ii) are conceived and reduced to practice by Dr. Frank McCormick after [***] and before [***]; and (iii) are solely assigned to or otherwise obtained by The Regents.

  

	1.11	 “Patent Rights” means the Valid Claims of, to the extent assigned to or otherwise obtained by The
Regents and/or Leidos, the following United States patents and patent applications: 

  

					
	 UC Case Number
	  	PCT Application Number	  	Filing or Issue Date
	 [***]
	  	[***]	  	[***]

 Patent Rights shall further include the Valid Claims of, to the extent assigned to or otherwise obtained by The Regents and/or
Leidos, the corresponding foreign patents and patent applications and any reissues, extensions, substitutions, continuations, divisions, and continuation-in-part
applications (but only those Valid Claims in the continuation-in-part applications that are entirely supported in the specification and entitled to the priority date of
the parent application). Further, The Regents agrees that it will not file or prosecute additional; patent applications, outside the scope of the Patent Rights, based on the invention disclosure existing as of the Effective Date that is identified
as [***]. For the avoidance of doubt, this definition of Patent Rights excludes any rights in and to Option Inventions, except as provided under Article 4. 
  

	1.12	 “Profit Sharing Income” means amounts received by Licensee under a sublicense agreement between
Licensee and a Sublicensee under which Licensee is funding a share of the development or commercialization costs of the Licensed Product and receives a share of net profit from such Sublicensee specifically resulting from any actual Licensed

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 4 

	 	
Product Sales that actually occurred. It does not, however, include any other amounts received by Licensee from such Sublicensee that are not [***], including but not limited to [***]. For the
avoidance of doubt, the negotiated Earned Royalty shall be paid on any such product Sales that give rise to such a Profit Sharing Income to Licensee. 

  

	1.13	 “Sale” means the act of selling, leasing or otherwise transferring, providing, or furnishing for use
for any consideration. 

  

	1.14	 “Sublicensee” means any person or entity (including any Affiliate) to which any of the license rights
granted to the Licensee hereunder are granted a sublicense or an option to a sublicense, but not including any subcontractors or vendors provided that Licensee is responsible for performance of such subcontractors in compliance with this Agreement
and that such subcontractors or vendors do not provide any cash or in-kind consideration to Licensee in exchange for Patent Rights. 

  

	1.15	 “Sublicensing Revenues” means amounts (including, without limitation, any [***], received by or
payable to the Licensee from any Sublicensee in consideration for the rights granted under a sublicense of the Licensee’s rights under this Agreement, provided that Sublicensing Revenues will not include amounts received by or payable to the
Licensee that are reasonably and fairly attributable to any of the following to the extent that each is bona fide: (a) [***] of the Licensee, (b) amounts received by the Licensee as the [***] of the Licensee;
(c) reimbursements to the Licensee of [***]; (d) reimbursement to the Licensee for [***] after the Effective Date of this Agreement, on the basis of [***]. 

 

	1.16	 “Therapeutic Licensed Product” means any Licensed Product, the composition of matter of which is
claimed by at least one Valid Claim included in the Patent Rights or any Licensed Service that uses such Licensed Product. For the avoidance of doubt, any Licensed Product covered by a claim that combines screening, composition of matter and/or
method of use in the same claim, shall be considered a Therapeutic Licensed Product. 

  

	1.17	 “Valid Claim” means a claim of a patent or patent application in any country that (i) has
not expired; (ii) has not been disclaimed; (iii) has not been cancelled or superseded, or if cancelled or superseded, has been reinstated; and (iv) has not been revoked, held invalid,

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 5 

	 	
or otherwise declared unenforceable or not allowable by a tribunal or patent authority of competent jurisdiction over such claim in such country from which no further appeal has or may be taken.

 2. GRANT 
  

	2.1	 Subject to the limitations and other terms and conditions set forth in this Agreement including the license
granted to the United States Government and those reserved by The Regents set forth in the Background and in Paragraphs 2.2.1 (obligations to the United States Government) and 2.4 (Government Requirements), The Regents grants to the Licensee an
exclusive license under its rights in and to Patent Rights to make, have made, use, Sell, offer for Sale and import Licensed Products, to provide Licensed Services, and to practice Licensed Methods, in the United States and in other countries where
The Regents may lawfully grant such Licenses, only in the Field of Use. 

  

	2.2	 The license granted in Paragraph 2.1 is subject to the following: 

 

	 	2.2.1	 The obligations to the United States Government under 35 U.S.C. §§ 200-212 and all applicable
governmental implementing regulations, as amended from time to time, including the obligation to report on the utilization of the Invention as set forth in 37 CFR. § 401.14(h), and all applicable provisions of any license to the United States
Government executed by The Regents; and 

  

	 	2.2.2	 the National Institutes of Health “Principles and Guidelines for Recipients of NIH Research Grants and
Contracts on Obtaining and Disseminating Biomedical Research Resources,” 64 F.R. 72090 (Dec. 23, 1999), as amended from time to time. 

  

	2.3	 Reservation of Rights. The Regents reserves and retains the right (and the rights granted to the
Licensee in this Agreement shall be limited accordingly), on behalf of itself and Leidos, to make, use and practice the Invention and any technology relating to any of the foregoing and to make and use any products and to practice any process that
is the subject of the Patent Rights (and to grant any of the foregoing rights to other educational and non-profit institutions) for educational and research purposes, including without limitation, any sponsored research performed for or on behalf of
commercial 

  
 6 

	 	
entities and including publication and other communication of any research results, provided that the right and interest of any such commercial entity shall be subject to the license granted to
Licensee under this Article 2. 

  

	2.4	 Government Requirements. Because the Invention was made under funding provided by the United States
Government, the parties agree to comply with the terms set forth in 35 U.S.C. § 204. The Regents will offer reasonable assistance in obtaining a waiver of these requirements upon Licensee’s request. 

 

	2.5	 Option Grant. To the extent it is lawfully able to, and subject to the limitations and other terms and
conditions set forth in this Agreement including the license granted to the United States Government set forth in the Background and in Paragraph 2.2.1 and the terms of the option set forth in Section 4 (Option), The Regents shall
(i) use commercially reasonable efforts to keep Licensee informed of the development of any Option Inventions, and (ii) shall grant the Licensee a time-limited, exclusive option on such Option Inventions as outlined in
Section 4. 

 3. SUBLICENSES 
  

	3.1	 Permitted Sublicensing. The Regents also grants to the Licensee the right to sublicense the rights
granted to the Licensee hereunder, through multiple tiers, to Affiliates and third parties, as long as the Licensee has current exclusive rights thereto under this Agreement. For purposes of this Agreement, any further sublicense granted by any
sublicensee will be considered a Sublicense and Licensee will ensure that such further sublicensees will be compliant with this Section 3.1. Licensee will ensure that each sublicense is subject to a written sublicense agreement. All sublicenses will
include all of the applicable rights of, and will require the performance of all the applicable obligations due to, The Regents (and, if applicable, the United States Government and other sponsors), other than those rights and obligations specified
in Article 6 (License Issue Fee), Article 7 (License Maintenance Fee) and Paragraph 9.2 (Minimum Annual Royalty) and Paragraphs 21.3 and 21.4 (reimbursement of Patent Prosecution Costs). For the purposes of this Agreement, the operations of all
Sublicensees shall be deemed to be the operations of the Licensee, for which the Licensee shall be responsible. 

  
 7 

	3.2	 Sublicense Requirements. The Licensee shall provide The Regents with a copy of each sublicense
issued within thirty (30) days of execution of such sublicense or sublicense amendment; collect and guarantee payment of all payments due The Regents from Sublicensees; and summarize and deliver all reports due The Regents from
Sublicensees. In the event that a Sublicensee does not pay payments owed to Licensee, Licensee shall use reasonable efforts, to obtain such owed and unpaid payments. If Licensee has (a) sent at least two (2) notices of default to its
Sublicensee by return receipt mail, or (b) its Sublicensee has not paid following efforts by a collection agency to obtain payment of such payments, then (i) if Licensee terminates the corresponding sublicense within such [***] period
and declares the uncollectable debt owed by Sublicensee to Licensee in Licensee’s books, then Sublicense Fees with respect to such uncollectible payments shall not be due to The Regents; provided that if such payments is actually paid to
Licensee thereafter, then Sublicense Fees with respect to such payments shall accrue to The Regents within [***] of the date that Licensee receives payment of such payments; or (ii)y if Licensee does not terminate the corresponding sublicense within
such [***], Licensee shall pay Sublicense Fees with respect to such payments, even though Licensee did not receive payment of such payments from its Sublicensee. 

 

	3.3	 Mandatory Sublicensing. If Licensee is unable or unwilling to serve or develop a potential market or
market territory for which there is a company willing to be a Sublicensee, Licensee will, at The Regents’ request, negotiate in good faith a Sublicense with any such Sublicensee. The Regents would like licensees to address unmet needs, such as
those of neglected patient populations or geographic areas, giving particular attention to improved therapeutics, diagnostics and agricultural technologies for the developing world. 

 

	3.4	 License Termination or Conversion to Non-Exclusive. Any sublicense granted hereunder shall survive any
early termination of this Agreement or conversion of this Agreement to a non-exclusive license, provided that: (i) the relevant Sublicensee is not in default of its sublicense and there are no Uncollectable Amounts, as defined in 1.9.5
associated with the Sublicensee, (ii) such Sublicensee agrees in writing to an assignment to The Regents of such sublicense; (iii) all of the terms of this Agreement are agreed to fully in writing by such Sublicensee; (iv)
such Sublicensee acquires no rights from or 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 8 

	 	
obligations on the part of The Regents other than those that, are specifically granted under this Agreement; and (v) such Sublicensee assumes all liability and obligations to The
Regents required of Licensee by this Agreement with respect to The Regents’ sublicensed rights, including past due obligations existing at the tune of assignment of this Agreement by Licensee. If any Sublicensee fails to meet the above
provisions described in this Paragraph 3.4 (i) - (v) then The Regents may terminate its sublicense, in accordance with Article 17 (Termination by The Regents). The Regents will not be bound to perform any duties or obligations set forth in any
sublicense to any Sublicensees that extend beyond the duties and obligations of The Regents set forth in this Agreement, and the Licensee’s obligations to The Regents hereunder will be binding upon each Sublicensee. Any such assignment will
include a modification to the sublicense that requires payment of all financial obligations (including, without limitation milestone payments and Earned Royalties) directly to The Regents by the Sublicensee as if it were the Licensee at a rate that
is no lower than the rate set forth in the applicable section of this Agreement, in accordance with Article 5 (Payment Terms). 

4. OPTION 
  

	4.1	 The Licensee shall have [***] from the day it received written notification from The Regents of an Option
Invention in which to notify The Regents in writing of Licensee’s desire to take a license to the Option Invention. If applicable and reasonable, such notification will identify the particular patent applications, patents, and territories for
which the Licensee wishes to obtain a license from The Regents and those for which it has no interest. 

  

	4.2	 The failure of the Licensee to so notify The Regents within the required time period will be deemed by The
Regents as an election by the Licensee not to secure a license to the Option Invention, and The Regents will then be free to market and license the Option Invention to others without any further obligation to the Licensee. 

 

	4.3	 If Licensee does elect to take a license for an Option Invention under Paragraph 4.1, Licensee will provide The
Regents with a written Plan of Commercialization for Licensed Products and Licensed Services within [***] of the effective date of such notification. A “Plan of Commercialization” is a reasonably detailed plan containing, but

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 9 

	 	
not limited to, the following information for each Licensed Product and Licensed Service: a plan and timetable for commercial development and market-introduction of each Licensed Product and
Licensed Service, including specific performance milestones representing technical achievements necessary for their commercialization and the date each such milestone will be met; projected Sales; the anticipated date of their first commercial Sale;
projected costs and profits; proposed financial terms for License; whether Licensee requests an exclusive or nonexclusive license; and other terms commonly included in business plans. The failure of the Licensee to provide a Plan of
Commercialization reasonable acceptable to The Regents will be deemed an election by the Licensee not to secure a license to the Option Invention, and The Regents will then be free to market and license the Option Invention to others without any
further obligation to the Licensee. 

  

	4.4	 If the Licensee exercises its rights under this Article 4 (Option) with respect to any Option Invention, for a
period for which not to exceed a total of [***] the Licensee and The Regents will, in good faith, negotiate the outstanding terms and conditions of a new license agreement (“New License Agreement”). The Regents has no obligation to file
any patent application for Option Invention but may do so at its own discretion or at the request of the Licensee. [***]. Notwithstanding any other provision of this Agreement to the contrary, neither party will be obligated to negotiate the New
License Agreement beyond [***] from the Licensee’s written election under Paragraph 4.1, unless the six month period is extended upon mutual written agreement of the parties. 

 

	4.5	 The parties mutually acknowledge that good-faith negotiations may not result in the execution of that New
License Agreement, but the parties will use reasonable efforts to reach agreement on commercially reasonable terms. 

  

	4.6	 The New License Agreement will include, but not be limited to, the following provisions, in a form similar to
this Agreement if appropriate: 

 [***]. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 10 

 5. PAYMENT TERMS 

 

	5.1	 Payment Obligations. Paragraphs 1.5, 1.6, 1.7, and 1.11 define Licensed Method, Licensed Product,
Licensed Service and Patent Rights, so that Earned Royalties are payable on products and methods covered by Valid Claims in both pending patent applications and issued patents. Earned Royalties will accrue in each country for the duration of the
Valid Claims contained in the Patent Rights in that country and will be payable to The Regents in accordance with Section 5.2.when Licensed Products or Licensed Services are invoiced, or if not invoiced, when delivered or otherwise exploited by
the Licensee or Sublicense in a manner constituting a Net Sale as defined in Paragraph 1.9. Sublicense Fees with respect to any Sublicensing Revenue shall accrue to The Regents within [***] of the date that such Sublicensing Revenue is received by
the Licensee provided that Licensee uses reasonable efforts to obtain such payments in accordance with Paragraph 3.2. 

  

	5.2	 Schedule. The Licensee will pay to The Regents all Earned Royalties, Sublicense Fees and other
consideration payable to The Regents [***]. Each payment will be for Earned Royalties, Sublicense Fees and other consideration which has accrued within the Licensee’s most recently completed calendar quarter. 

 

	5.3	 Currency. All consideration due The Regents will be payable and will be made in United States dollars by
check payable to “The Regents of the University of California” or by wire transfer to an account designated by The Regents. The Licensee is responsible for all bank or other transfer charges. When Licensed Products or Licensed Services are
Sold for monies other than United States dollars, the Earned Royalties and other consideration will first be determined in the foreign currency of the country in which such Licensed Products or Licensed Services were Sold and then converted into
equivalent United States dollars. The exchange rate will be the average exchange rate quoted in the The Wall Street Journal during the last thirty (30) days of the reporting period. 

 

	5.4	 Taxes. Sublicense Fees and Earned Royalties on Net Sales of Licensed Products or Licensed Services and
other consideration accrued in, any country outside the United States may not be reduced by any taxes, fees or other charges imposed by the government of such country, except those taxes, fees and charges allowed under the provisions of Paragraph
1.9 (Net Sales). 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 11 

	5.5	 Accrual. In the event that any patent or claim thereof included within the Patent Rights is held invalid
in a final decision by a court of competent jurisdiction and last resort and from which no appeal has or can be taken, then all obligation to pay royalties based on that patent or claim or any claim patentably indistinct therefrom will cease as of
the date of final decision. The Licensee will not, however, be relieved from paying any royalties that accrued before such final decision and the Licensee shall be obligated to pay the full amount of royalties due hereunder to the extent that The
Regents licenses one or more Valid Claims within the Patent Rights to the Licensee with respect to Licensed Products or Licensed Services. 

  

	5.6	 Late Payments. In the event that royalties, fees, reimbursements for Patent Prosecution Costs or other
monies owed to The Regents are not received by The Regents when due, the Licensee will pay to The Regents interest at a rate of [***], or the maximum amount allowable by law, whichever is lower. Such interest will be calculated from the date payment
was due until actually received by The Regents. Such accrual of interest will be in addition to and not in lieu of, enforcement of any other rights of The Regents due to such late payment. 

6. LICENSE ISSUE FEE 
  

	6.1	 The Licensee will pay to The Regents a license issue fee of seventy five thousand dollars ($75,000) within
[***] of the Effective Date. This fee is non-refundable, non-cancelable and is not an advance or otherwise creditable against any royalties or other payments required to
be paid under the terms of this Agreement. 

 7. LICENSE MAINTENANCE FEE 

 

	7.1	 The Licensee will also pay to The Regents a license maintenance fee as follows: 

 

	 	7.1.1	 [***] on [***]. 

  

	 	7.1.2	 [***] beginning on the [***] and continuing annually on each subsequent anniversary of the Effective Date.

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 12 

	 	7.1.3	 Notwithstanding the payment obligations set forth in Section 7.1.1 and 7.1.2, license maintenance fee is
not due on any anniversary of the Effective Date if on that date, the Licensee is Selling or otherwise exploiting Licensed Products or Licensed Services and is paying an Earned Royalty to The Regents on the Net Sales of such Licensed Product or
Licensed Service. The license maintenance fee is non-refundable and is not an advance or otherwise creditable against any royalties or other payments required to be paid under the terms of this Agreement.

 8. PAYMENTS ON SUBLICENSES 
  

	8.1	 The Licensee will pay to The Regents the following non-refundable and non-creditable sublicense fees (“Sublicense Fees”): 

  

	 	8.1.1	 [***] percent ([***]%) of all Sublicensing Revenues received prior to [***]. 

 

	 	8.1.2	 [***] percent ([***]%) of all Sublicensing Revenues received after [***] but prior to [***].

  

	 	8.1.3	 [***] percent ([***]%) of all Sublicensing Revenues received after [***]. 

9. EARNED ROYALTIES AND MINIMUM ANNUAL ROYALTIES 
  

	9.1	 Earned Royalty. The Licensee will pay to The Regents an Earned Royalty as described below on the Net
Sales of each Licensed Product or Licensed Service subject to the terms and conditions of this Agreement (“Earned Royalty”): 

  

	 	9.1.1	 For each Therapeutic Licensed Product 

 

	 	9.1.1.1	 [***] up to the portion of annual Net Sales of the applicable Therapeutic Licensed Product under [***] and;

  

	 	9.1.1.2	 [***] for the portion of annual Net Sales of the applicable Therapeutic Licensed Product above [***].

  

	 	9.1.2	 For Method of Use Licensed Products 

 

	 	9.1.2.1	 [***]. 

  

	 	9.1.3	 A Licensed Product will be paid royalties at either the rates set forth in 9.1.1 or 9.1.2 above, but not both.
For the avoidance of doubt, the method of use rate will 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 13 

	 	
apply to Method of Use Licensed Products that are covered by method of use claims of the Patent Rights only and in which the therapeutic product utilizing the method of use claim is not a
Therapeutic Licensed Product. 

  

	9.2	 Minimum Annual Royalty. The Licensee will also pay to The Regents a minimum annual royalty of [***] for
the life of Patent Rights, beginning with the year of the first Sale of Licensed Product or Licensed Service. The minimum annual royalty will be paid to The Regents by [***] and will be credited against the Earned Royalty due for the calendar year
in which the minimum payment was made. Licensee’s obligation to pay the minimum annual royalty will be pro-rated for the number of months remaining in the calendar year when Sales commence and will be due
the following [***] (along with the minimum annual royalty payment for that year), to allow for crediting of the pro-rated year’s Earned Royalties. 

10. MILESTONE PAYMENTS 
  

	10.1	 With respect to each Licensed Product, the Licensee will pay to The Regents the following one-time per Licensed Product, non-refundable, non-creditable amounts: 

 

	 	10.1.1	 For the first indication for each Licensed product: 

[***] 
  

	 	10.1.2	 For the second indication for each Licensed Product: 

[***] 
  

	10.2	 For the avoidance of doubt, each of the milestone payments set forth in Paragraphs 10.1.1 and 10.1.2 will be
payable with respect to each Licensed Product and regardless of whether the applicable milestone event has been achieved by the Licensee, Sublicensee, or any Affiliate, provided that, if Licensee discontinues the development and/or commercialization
of a particular Licensed Product and instead develops and/or commercializes another Licensed Product in place of such discontinued Licensed Product, then Licensee shall not be required to make any milestone payments for such second Licensed Product
for any milestone events that have already triggered Licensee’s milestone payment obligations for the discontinued Licensed Product for that particular indication. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 14 

	10.3	 All milestone payments set forth in Paragraphs 10.1 are due to The Regents within [***] of the occurrence of
the applicable milestone event. 

 11. INDEXED MILESTONE 

 

	11.1	 Within [***] of the Indexed Milestone Event (as defined in 11.4 below), the Licensee will pay to The Regents a
cash payment (“Indexed Milestone Payment”) equal to N times $P, where: 

  

	 	11.1.1	 N shall be the number equivalent of the number of shares equal to [***] of the then-outstanding shares of
common stock of Licensee (assuming full conversion of all then-outstanding preferred stock and convertible securities and full exercise of any then-outstanding options and warrants) calculated on an
as-converted basis as of immediately after the closing of a Licensee Financing (as defined in Paragraph 11.6 below); and 

 

	 	11.1.2	 $P shall be 

  

	 	11.1.2.1	 in the case of an IPO (as defined in 11.3 below), the offering price per share of the securities sold to the
underwriters at the closing of the IPO (net of any underwriting discounts and commissions), or 

  

	 	11.1.2.2	 in the case of a Change of Control Transaction (as defined in 11.5 below), the per share consideration
(including the fair market value of any non-cash consideration paid by such acquiring third party therefore) that would be received by the Licensee’s stockholders in the Change of “^Control
Transaction, calculated after payment to the Licensee’s preferred shareholders of the aggregate of capital invested in the Licensee by such preferred shareholders provided that such payment, including any fair market value of non-cash consideration, shall not be greater than [***] amount of capital invested in the Licensee by such preferred shareholders. Any amounts received from any earn-out
escrow, milestones and/or other deferred payments would be considered and subsequently paid to the Regents as $P when the actual cash or amounts are distributed to Licensee’s holders of common stock. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 15 

	11.2	 N shall be adjusted in the same manner as the common stock in the event of a reverse or forward split of
Licensee’s stock, any dividends, a recapitalization or other similar adjustment subsequent to the Licensee Financing. For the avoidance of doubt, calculation of such share number shall be treated no differently than other issued or outstanding
common stock of the Licensee and specifically The Regents’ interest will not be subject to any greater dilution than the interest of any other holder of Licensee’s common stock. 

 

	11.3	 “IPO” means an initial public offering of the equity securities of the Licensee or a
subsidiary of Licensee pursuant to a registration statement filed with the Securities and Exchange Commission or a similar filing on an international exchange or market. 

 

	11.4	 “Indexed Milestone Event” means the earlier to occur of (i) an IPO and (ii) a
Change of Control Transaction. 

  

	11.5	 “Change of Control Transaction” means; the first acquisition, consolidation, merger,
reorganization or other transaction or series of transactions in which (x) either (i) Licensee is a constituent party or (ii) a subsidiary of Licensee is a constituent party and the licensee issues shares of its capital stock
pursuant to such transaction, and (y) pursuant to which greater than fifty percent (50%) of the voting power of Licensee or subsidiary of Licensee is transferred to a third party. However, a transaction involving a third party will not
be considered as a Change of Control Transaction if such transaction or series of transactions does not provide liquidity to at least a majority of Licensee’s stockholders, existing prior such transaction, either in the form of cash or stock
that is freely tradable and listed on a national or international securities exchange or market. 

  

	11.6	 “Licensee Financing” means the first issuance after the Effective Date of equity securities of
the Licensee in a bona fide financing transaction or a series of related bona fide financing transactions with aggregate proceeds to Licensee of at least forty five million dollars $45,000,000(including the conversion of any convertible debt) and in
which the proceeds to be received by Licensee are principally from investors who are venture capital, private equity, or similar investors. 

  
 16 

	11.7	 Notwithstanding the above, in the event that a Change of Control Transaction or IPO occurs prior to the
Licensee Financing date, the Indexed Milestone Payment shall be equal to the greater of a) N times $P, where $P is determined as in 11.1.2.2 above, and where N equals [***] of the then-outstanding shares of Licensee (assuming foil conversion of all
then-outstanding convertible securities and full exercise of any then-outstanding options and warrants) immediately after the closing of a Change of Control Transaction, and (b) [***]. 

 

	11.8	 The Indexed Milestone Payment shall be a one-time payment obligation
(other than any payments from an earn-out, escrow, milestone or other deferred consideration, or similar arrangement which shall be paid as and when received by the Licensee or its equity holders) and will
survive termination or expiration of the license agreement. Payment of the Indexed Milestone Payment shall be in priority and preference to payment to any holders of equity securities of the Licensee. 

12. PARTICIPATION RIGHTS 
  

	12.1	 If the Licensee proposes to sell any equity securities or securities that are convertible into equity
securities of the Licensee, then The Regents and/or its Assignee (as defined below) will have the right to purchase up to [***] of the securities issued in each offering on the same terms and conditions as are offered to the other purchasers in each
such financing. Licensee shall provide [***] advanced written notice of each such financing, including reasonable detail regarding the terms and purchasers in the financing. The term “Assignee” means (a) any entity to which Licensee
has consented to the assignment of The Regents’ participation rights under this section, or (b) any entity that is controlled by The Regents. This paragraph shall survive the termination of this agreement. Licensee hereby consents
to assignment of the participation rights of The Regents to [***]. 

 13. DUE DILIGENCE 

 

	13.1	 The Licensee, upon execution of this Agreement, will diligently proceed with the development, manufacture and
Sale of at least one (1) Licensed Products and/or Licensed Services and will earnestly and diligently market the same after receipt of any requisite regulatory approvals and in quantities sufficient to meet the market demands therefor.

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 17 

	13.2	 The Licensee or a Sublicensee will obtain all necessary governmental approvals in each country where Licensed
Products or Licensed Services are manufactured, used, Sold, offered for Sale or imported. 

  

	13.3	 The Licensee will: 

[***] 
 The Regents recognizes
that there are uncertainties associated with the development of therapeutic products and the regulatory process required by the FDA (and Foreign regulatory authorities that are equivalent to the FDA), and that it may be necessary from time to time
to amend one or more of the milestones under Paragraphs 13.3,3.2 through 13.3.3.6. Accordingly, if Licensee is unable to meet one or more of such specified milestones and Licensee demonstrates to The Regents, based on the Regents’ reasonable,
objective, good faith assessment of Licensee’s demonstration and supporting documentation, that Licensee has used and is using Licensee’s diligent efforts (with supporting documentation) to meet such milestone and [***], then upon
submission in writing by Licensee to The Regents of the aforementioned diligent efforts and a plan to overcome such regulatory hurdles, The Regents will extend the deadline for each such milestone under Paragraphs 13.3.1 through 13.3.3.7 for a
[***], provided Licensee also has paid to The Regents a fee, for each such extension, [***]. An extension of one milestone will extend all remaining milestones in Paragraphs 13.3.1 through 13.3.3.7 by the same extension time period. 

and 
  

	 	13.3.1	 use commercially reasonable efforts to fill the market demand for Licensed Products and Licensed Services
following commencement of marketing at any time. 

  

	13.4	 If the Licensee is unable to perform any of the above provisions, [***]. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 18 

 14. PROGRESS AND ROYALTY REPORTS 

 

	14.1	 Progress Reports. Beginning on June 30, 2017, and semiannually thereafter, Licensee will
submit a written summary report to The Regents covering the Licensee’s (and any Affiliates’ or Sublicensees’) activities related to this Agreement. The report will include information sufficient to enable The Regents to satisfy
reporting requirements of the U.S. Government and to ascertain progress by Licensee toward meeting this Agreement’s diligence requirements set forth in Article 13 (Due Diligence). Each report will describe, where relevant: progress toward
commercialization of Licensed Products and Licensed Services, including work completed, identification of key scientific discoveries, summary of work in progress, current schedule of anticipated events or milestones, market plans for introduction of
Licensed Products and Licensed Services, and significant corporate transactions involving Licensed Products and Licensed Services. Notwithstanding the foregoing, Licensee shall be deemed to have fulfilled its obligations under this
Section 14.1 if such report is generated using the standard form provided by The Regents for such reporting purposes and that such form is filled out with sufficient detail as determined by the Licensing Professional responsible for the
oversight of this Agreement. All information contained in such reports shall be deemed Proprietary Information of Licensee. 

  

	14.2	 First Sale. The Licensee will report to The Regents the date of first Sale of a Licensed Product or
Licensed Service in each country in its first progress and royalty reports following such first Sale of a Licensed Product or Licensed Service. 

  

	14.3	 Royalty Reports. Beginning with the earlier of (i) the first Sale of a Licensed Product or
Licensed Service or (ii) the first transaction that results in Sublicense Fees accruing to The Regents, the Licensee shall make quarterly royalty reports to The Regents on or before each February 28, May 31,
August 31 and November 30 of each year. Each royalty report will [***]. All information contained in such royalty reports shall be deemed Proprietary Information of Licensee. 

 

	14.4	 Entity Status. The Licensee has a continuing responsibility to keep The Regents informed of the
large/small business entity status (as defined by the United States Patent and Trademark Office) of itself and its Sublicensees and Affiliates. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 19 

 15. BOOKS AND RECORDS 

 

	15.1	 Accounting. The Licensee shall keep accurate books and records showing all Licensed Products and
Licensed Services manufactured, used, and/or Sold under the terms of this Agreement. Books and records must be preserved for at least five (5) years from the date of the royalty payment to which they pertain. 

 

	15.2	 Auditing. Books and records must be open to inspection by representatives or agents of The Regents at
reasonable times during normal business hours with reasonable notice of at least two (2) weeks, and such inspections shall not exceed more than once per calendar year. The Regents shall bear the fees and expenses of examination but if an
error in royalties of more than [***] of the total royalties due for any year is discovered in any examination then the [***] of that examination and shall [***] of the examination results. Any information obtained by The Regents during such
inspection shall be deemed Proprietary Information of Licensee. 

 16. LIFE OF THE AGREEMENT 

 

	16.1	 Term. Unless otherwise terminated by operation of law, Paragraph 16.2 (Bankruptcy), or by acts of the
parties in accordance with the terms of this Agreement, this Agreement will remain in effect from the Effective Date until, on a Licensed Product-by-Licensed Product and country-by-country basis, the expiration or abandonment of the last of the
Valid Claim within a Patent Rights licensed hereunder. Notwithstanding Section 16.3 below, upon the expiration of this Agreement in a particular country for a particular Licensed Product, Licensee’s obligation to make earned royalty
payment under Section 9.1 shall expire with; respect to such Licensed Product made, used, Sold, offered for Sale or imported, Licensed Service offered, or Licensed Method practiced in such country after such termination. Furthermore,
Licensee’s obligation to make minimum royalty payment under Section 9.2 shall expire after the expiration of any and all earned royalty obligations with respect to any and all Licensed Products and/or Licensed Services then being
developed and/or commercialized by or on behalf of Licensee except that except that Earned Royalties shall be due in accordance with this Agreement on any Licensed Products and/or Licensed Services made prior to the expiration of this Agreement.

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 20 

	16.2	 Bankruptcy. This Agreement will automatically terminate without the obligation to provide [***] notice
as set forth in Paragraph 17.1 (Termination By The Regents) upon the filing of a petition for relief under the United States Bankruptcy Code by or against the Licensee as a debtor or alleged debtor, provided that such filing is not withdrawn or
otherwise dismissed within such [***]. 

  

	16.3	 Surviving Provisions. Any termination or expiration of this Agreement will not affect the rights and
obligations set forth in the following Articles: 

  

			
	Article 1	  	Definitions
	Paragraph 5.6	  	Late Payments
	Article 6	  	License Issue Fee
	Article 8	  	Payments on Sublicenses
	Paragraphs 9.1 and 9.2	  	Earned Royalties and Minimum Annual Royalties
	Article 11	  	Indexed Milestone
	Article 12	  	Participation Rights
	Article 15	  	Books and Records
	Article 16	  	Life of the Agreement
	Article 18	  	Use of Names and Trademarks
	Article 19	  	Limited Warranty
	Article 20	  	Limitation of Liability
	Paragraphs 21.3 and 21.4	  	Patent Prosecution Costs and Effects of Termination
	Article 24	  	Indemnification
	Article 25	  	Notices
	Article 28	  	Governing Laws; Venue
	Article 31	  	Confidentiality

  

	16.4	 Effects of Termination. The termination or expiration of this Agreement will not relieve the Licensee of
its obligation to pay any fees, royalties or other payments owed to The Regents at the time of such termination or expiration and will not impair any accrued right of The Regents, including the right to receive Earned Royalties in accordance with
Article 9 (Earned Royalties and Minimum Annual Royalties). 

 17. TERMINATION 

 

	17.1	 By The Regents. If the Licensee commits a Material Default of this Agreement, then The Regents may give
written notice of default (Notice of Default) to the Licensee. A “Material Default” includes, but is not limited to: the failure of Licensee to: (i) perform any of its sublicensing obligations set forth in Article 3, (ii) make
any payment in accordance with Articles 5, 6, 7, 8, 9,10 and 11; (iii) perform the diligence obligations 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 21 

	 	
described in Article 13; (iv) submit the progress and royalty reports in accordance with Article 14; or (iv) indemnify an Indemnitee in accordance with Section 24.1. If
the Licensee fails to repair the default within [***] of the effective date of Notice of Default, The Regents may terminate this Agreement and its licenses by a second written notice (Notice of Termination). If a Notice of Termination is sent to the
Licensee, this Agreement will automatically terminate on the effective date of that notice. 

  

	17.2	 By Licensee. The Licensee, has the right at any time to terminate this Agreement by providing a Notice
of Termination to The Regents. Moreover, the Licensee will be entitled to terminate the rights under Patent Rights on a country-by-country basis by giving notice in writing to The Regents. Termination of this Agreement (but not termination of any
patents or patent applications under Patent Rights, which termination is subject to Paragraph 21.4 (Effects of Termination) will be effective [***] from the date such termination notice is sent by Licensee. 

 

	17.3	 Immediate Termination. The Agreement will terminate with [***] written notification if the Licensee
files a claim that includes in any way the assertion that any portion of The Regents’ Patent Rights is invalid or unenforceable whether the filing is by Licensee, a third party on behalf of Licensee, or a third party at the written urging of,
or with the assistance of, the Licensee, provided that such termination shall not become effective if Licensee withdraws or causes the withdrawal of such claim within such [***] notice period. Licensee shall not be construed as having breached this
Section 17.3 if Licensee’s action is in connection with any claim of infringement asserted, alleged or filed by or on behalf of the Regents against Licensee or any of its Affiliates and/or sublicensees. 

18. USE OE NAMES AND TRADEMARKS 
  

	18.1	 Nothing contained in this Agreement will be construed as conferring any right to either party to use in
advertising, publicity or other promotional activities any name, trade name, trademark or other designation of the other party (including a contraction, abbreviation or simulation of any of the foregoing). Without the Licensee’s consent
case-by-case, The Regents may list Licensee’s name as a licensee of technology from The Regents and identify Licensee as a UCSF startup without further identifying the 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 22 

	 	
technology. Unless required by ‘ law or unless consented to in writing by Director of Technology Management, Office of Innovation, Technology, and Alliances, the use by the Licensee of the
name “The Regents of the University of California” or the name of any campus of the University of California in advertising, publicity or other promotional activities is expressly prohibited, except that Licensee shall have the right to
state the fact that The Regents is the licensor of the Patent Rights without obtaining the prior consent of The Regents 

19. LIMITED WARRANTY 
  

	19.1	 To the extent of the knowledge of the licensing professional administering this Agreement and as of the
Effective Date, The Regents warrants to the Licensee that (a) it is the joint owner of the Patent Rights with Leidos, which is the National Cancer Institute’s Operations and Technical Support (OTS) contractor to the Frederick
National Laboratory for Cancer Research (FNLCR), a Federally Funded Research and Development Center (FFRDC) and a Federal Laboratory; (b) The Regents is the party having the sole and exclusive right to grant any commercial rights under
the Patent Rights on behalf of both The Regents and Leidos; (c) neither The Regents nor Leidos has granted any option or license, or otherwise transferred or encumbered any Patent Rights, prior to the Effective Date with the exception of
the statutorily required government license; and (d) The Regents has the lawful right to grant this license. The Regents agree that, during the Term, it will first notify Licensee in writing and discuss with Licensee in good faith any
proposed modification or termination of the IIA before any such modification or termination becomes effective. 

  

	19.2	 Except as expressly set forth in this Agreement, this license and the associated Invention, Patent Rights,
Licensed Products, Licensed Services, and Licensed Methods are provided by The Regents WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. THE REGENTS- MAKES NO EXPRESS OR
IMPLIED REPRESENTATION OR WARRANTY THAT THE INVENTION, PATENT RIGHTS, LICENSED PRODUCTS, LICENSED SERVICES OR LICENSED METHODS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER RIGHTS. 

  
 23 

	19.3	 This Agreement does not: 

 

	 	19.3.1	 express or imply a warranty or representation as to the validity, enforceability, or scope of any Patent
Rights; or 

  

	 	19.3.2	 express or imply a warranty or representation that anything made, used, Sold, offered for Sale or imported or
otherwise exploited under any license granted in this Agreement is or will be free from infringement of patents, copyrights, or other rights of third parties; or 

 

	 	19.3.3	 obligate The Regents to bring or prosecute actions or suits against third parties for patent infringement
except as provided in Article 23 (Patent Infringement); or 

  

	 	19.3.4	 confer by implication, estoppel or otherwise any license or rights under any patents or other rights of The
Regents other than Patent Rights, regardless of whether such patents are dominant or subordinate to Patent Rights; or 

  

	 	19.3.5	 obligate The Regents to furnish any advancements, developments, or other improvements to Patent Rights which
are not entitled to the priority dates of Patent Rights, or know-how, technology or information not provided in Patent Rights; or 

20. LIMITATION OF LIABILITY 
  

	20.1	 EXCEPT AS SET FORTH IN SECTION 24 (INDEMNIFICATION), NEITHER PARTY WILL BE LIABLE FOR ANY LOST PROFITS, COSTS
OF PROCURING SUBSTITUTE GOODS OR SERVICES, LOST BUSINESS, ENHANCED DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT OR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR OTHER SPECIAL DAMAGES SUFFERED BY THE OTHER PARTY ARISING OUT OF OR RELATED TO
THIS AGREEMENT FOR ALL CAUSES OF ACTION OF ANY KIND (INCLUDING TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

  
 24 

 21. PATENT PROSECUTION AND MAINTENANCE 

 

	21.1	 Patent Prosecution. As long as the Licensee has paid patent costs as provided for in this Article, The
Regents shall diligently endeavor to prosecute and maintain the United States and foreign patents comprising Regents’ Patent Rights using counsel of its choice. The Regents will provide the Licensee with copies of all relevant documentation so
that the Licensee will be informed of the continuing prosecution and may comment upon such documentation sufficiently in advance of any initial deadline for filing a response (and The Regents shall incorporate such comments when appropriate and/or
reasonable), provided, however, that if the Licensee has not commented upon such documentation in a reasonable time for The Regents to sufficiently consider the Licensee’s comments prior to a deadline with the relevant government patent office,
or The Regents must act to preserve the Patent Rights, The Regents will be free to respond without consideration of the Licensee’s comments, if any. The Licensee agrees to keep this documentation confidential. The Regents’ counsel will
take instructions only from The Regents, and all patents and patent applications under this Agreement will be assigned solely to The Regents. The Regents shall use all reasonable efforts to amend any patent application to include claims reasonably
requested by the Licensee to protect the products contemplated to be sold under this Agreement and to file and prosecute patents in foreign countries indicated by and [***]. 

 

	21.2	 Patent Term. The Licensee may apply for an extension of the term of any patent included within
Regents’ Patent Rights if appropriate under the Drug Price Competition and Patent Term Restoration Act of 1984 and/or European, Japanese and other foreign counterparts of this Law. If the Licensee, at its commercially-reasonable discretion,
elects to file for such an extension, it shall prepare all documents, and The Regents agrees to execute the documents and to take additional action as the Licensee reasonably requests in connection therewith. 

 

	21.3	 Costs. [***] of preparing, filing, prosecuting and maintaining all United States and foreign patent
applications contemplated by this Agreement (“Patent Prosecution Costs”). Patent Prosecution Costs billed by [***] counsel during the term of the Agreement and for the three (3) month period after a Notice of Termination as set
forth in Paragraph 21.4 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 25 

	 	
(Effects of Termination) below will be rebilled to the [***] and are due within [***] of rebilling by [***]. These Patent Prosecution Costs will include, without limitation, patent prosecution
costs for the Invention incurred by [***] prior to the execution of this Agreement and any patent prosecution costs that may be incurred for patentability opinions, re-examination, re-issue, interferences, oppositions or inventorship determinations.
Prior Patent Prosecution Costs will be due upon execution of this Agreement and billing by [***] and are at least [***]. 

  

	21.4	 Effects of Termination. The [***] will be obligated to pay any Patent Prosecution Costs incurred during
the [***] period after receipt by either party of a Notice of Termination, even if the invoices for such Patent Prosecution Costs are received by the [***] after the end of the [***] period following receipt of a Notice of Termination. The [***] may
terminate its obligation to pay Patent Prosecution Costs with respect to any given patent application or patent under Patent Rights in any or all designated countries upon [***] written notice to [***]. The Regents may continue prosecution and/or
maintenance of such application(s) or patent(s), and applications in foreign countries where Licensee has elected not to file, at its sole discretion [***] and Licensee will have no further right or licenses thereunder. For the avoidance of doubt,
the written notification in the previous sentence shall not relieve [***] from the obligation to [***] for such Patent Prosecution Costs in connection therewith incurred during the [***] period following such notice. Non-payment of Patent
Prosecution Costs may be deemed by [***] as an election by the [***] not to maintain such application(s) or patent(s). 

22. PATENT MARKING 
  

	22.1	 The Licensee will mark all Licensed Products made, used or Sold under the terms of this Agreement or their
containers in accordance with the applicable patent marking laws. 

 23. PATENT INFRINGEMENT 

 

	23.1	 Infringement Notice. In the event that The Regents (to the extent of the knowledge of the licensing
professional responsible for the administration of this Agreement) or the Licensee learns of infringement of potential commercial significance of any patent licensed under this Agreement, the knowledgeable party will provide the other
(i) with written notice of such infringement and (ii) with any evidence of such infringement 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 26 

	 	
available to it (the “Infringement Notice”). During the period in which, and in the jurisdiction where, the Licensee has exclusive rights under this Agreement, neither The Regents nor
the Licensee will notify a possible infringer of infringement or put such infringer on notice of the existence of any Patent Rights without first obtaining consent of the other. If the Licensee puts such infringer on notice of the existence of any
Patent Rights with respect to such infringement without first obtaining the written consent of The Regents and if a declaratory judgment action is filed by such infringer against The Regents, then Licensee’s right to initiate a suit against
such infringer for infringement under Paragraph 23.2 (Company Suit and Joining) below will terminate immediately without the obligation of The Regents to provide notice to the Licensee. Both The Regents and the Licensee will use their diligent
efforts to cooperate with each other to terminate such infringement without litigation. 

  

	23.2	 Company Suit and Joining. If infringing activity of potential commercial significance by the infringer
has not been abated within [***] following the date the Infringement Notice takes effect, then the Licensee may institute suit for patent infringement against the infringer. The Regents may voluntarily join such suit, at its own expense, but may not
otherwise commence suit against the infringer for the acts of infringement that are the subject of the Licensee’s suit or any judgment rendered in that suit. The Licensee may not join The Regents as a party in a suit initiated by the Licensee
without The Regents’ prior written consent. If The Regents joins a suit initiated by the Licensee, then the Licensee will pay any costs incurred by The Regents arising out of such suit, including but not limited to, any legal fees of counsel
that The Regents selects and retains to represent it in the suit. 

  

	23.3	 Regents’ Suit. If, within a [***] following the date the Infringement Notice takes effect,
infringing activity of potential commercial significance by the infringer has not been abated and if the Licensee has not brought suit against the infringer, then The Regents may institute suit for patent infringement against the infringer. If The
Regents institutes such suit, then the Licensee may not join such suit without The Regents’ consent and may not thereafter commence suit against the infringer for the acts of infringement that are the subject of The Regents’ suit or any
judgment rendered in that suit. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 27 

	23.4	 Infringement Notice. Notwithstanding anything to the contrary in this Agreement, in the event that the
infringement or potential infringement pertains to an issued patent included within the Patent Rights and written notice is given under the Drag Price Competition and Patent Term Restoration Act of 1984 (and/or foreign counterparts of this Law),
then the party in receipt of such notice under the Act (in the case of The Regents to the extent of the actual knowledge of the licensing officer responsible for the administration of this Agreement) shall provide the Infringement Notice to the
other party promptly. If the time period is such that the Licensee will lose the right to pursue legal remedy for infringement by not notifying a third party or by not filing suit, the notification period and the time period to file suit will be
accelerated to within [***] of the date of such notice under the Act to either party. 

  

	23.5	 Recovery. Any recovery or settlement received in connection with any suit will first be shared by The
Regents and the Licensee equally to cover any litigation costs each incurred and next shall be paid to The Regents or the Licensee to cover any litigation costs it incurred in excess of the litigation costs of the other. In any suit initiated by the
Licensee, any recovery in excess of litigation costs will be shared between Licensee and The Regents as follows: (a) for any recovery other than amounts paid for willful infringement: (i) The Regents will receive [***] of the
recovery if The Regents was not a party in the litigation and did not incur any litigation costs associated with the use of outside counsel, (ii) The Regents will receive [***] of the recovery if The Regents was a party in the litigation
whether joined as a party under the provisions of Paragraph 23.2 (Company Suit and Joining) or otherwise, but The Regents did not incur any litigation costs, and (iii) The Regents will receive [***] of the recovery if The Regents
incurred any litigation costs associated with the use of outside counsel in connection with the litigation; and (b) for any additional recovery obtained based on a ruling of willful infringement, The Regents will receive, [***] of such
additional the recovery, provided that, in each the case of (a) and (b), The Regents shall only be deemed to have incurred any outside counsel litigation costs to the extent the Licensee has not reimbursed The Regents for such costs. In
any suit initiated by The Regents, any recovery in excess of litigation costs will belong to The Regents. The Regents and the Licensee agree to be bound by all determinations of patent infringement, validity and enforceability (but no other issue)
resolved by any adjudicated judgment in a suit brought in compliance with this Article 23 (Patent Infringement). 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 28 

	23.6	 Sublicenses. Any agreement made by the Licensee for purposes of settling litigation or other dispute
shall comply with the requirements of Article 3 (Sublicenses) of this Agreement. 

  

	23.7	 Cooperation. Each party will cooperate with the other in any litigation proceedings instituted
hereunder, provided that such cooperation shall be at the expense of the party who initiated the suit (unless such suit is being jointly prosecuted by the parties). 

 

	23.8	 Control. Any litigation proceedings will be controlled by the party bringing the suit, except that each
Party may be represented by counsel of its choice in any suit brought by the Licensee, 

 24. INDEMNIFICATION 

 

	24.1	 Indemnification. The Licensee will, and will require its Sublicensees to, indemnify, hold harmless and
defend The Regents, the sponsors of the research that led to the Invention and the inventors of any invention claimed in patents or patent applications under Patent Rights (including the Licensed Products, Licensed Services and Licensed Methods
contemplated thereunder) and their employers, and the officers, employees and agents of any of the foregoing, against any and all third party claims, suits, losses, damages, costs, fees and expenses resulting from, or arising out of, the exercise of
this license or any sublicense. This indemnification will include, but not be limited to, any product liability claims. If The Regents believes that there will be a conflict of interest or it will not otherwise be adequately represented by counsel
chosen by the Licensee to defend The Regents in accordance with this Paragraph 24.1, then The Regents may retain counsel of its choice to represent it and will pay all expenses for such representation. 

 

	24.2	 Insurance. The Licensee, at its sole cost and expense, will insure its activities in connection with any
work performed hereunder and will obtain, keep in force, and maintain general liability insurance with a limit no less than [***] prior to or coinciding with the Effective Date of this Agreement consistent with sound business practices.

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 29 

	 	
Commencing with the dosing of the first subject in the first Phase I clinical trial such insurance levels will be at least as follows: 

 

	 	24.2.1	 Commercial Form General Liability Insurance (contractual liability included) with limits as follows:

  

	 	24.2.2	 Each Occurrence [***] 

 

	 	24.2.3	 Products/Completed Operations Aggregate [***] 

 

	 	24.2.4	 Personal and Advertising Injury [***] 

 

	 	24.2.5	 General Aggregate (commercial form only) [***] 

(if written on a claims-made form, it shall continue for [***] following termination or expiration of this Agreement). 

 

	24.3	 Upon the employment of the first employee by Licensee, worker’s compensation as legally required in the
jurisdiction in which the Licensee is doing business. 

  

	24.4	 The coverage and limits above will not in any way limit the Licensee’s liability under this Article 24
(Indemnification.) 

  

	24.5	 Certificates. Upon the execution of this Agreement, the Licensee will furnish The Regents with
certificates of insurance evidencing compliance with all requirements. Such certificates will:, indicate The Regents as an additional insured(s) under the coverage described above in Paragraph 24.2 (Insurance); and include a provision that the
coverage will be primary and will not participate with, nor will be excess over, any valid and collectable insurance or program of self-insurance maintained by The Regents. 

 

	24.6	 Notification. The Regents will promptly notify the Licensee in writing of any claim or suit brought
against The Regents for which The Regents intends to invoke the provisions of this Article 24 (Indemnification). The Licensee will control the defense and settlement of any claims pursuant to this Article 24, and will keep the Regents informed of
its defense of any claims pursuant.to this Article 24 (Indemnification), except that Licensee may not settle any claims absent the Regents’ prior written consent. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 30 

 25. NOTICES 
  

	25.1	 Any notice or payment hereunder shall be deemed to have been properly given when sent in writing in English to
the respective address below and shall be deemed effective: 

  

	 	25.1.1	 on the date of delivery if delivered in person, 

 

	 	25.1.2	 on the date of mailing if mailed by first-class certified mail, postage paid, or 

 

	 	25.1.3	 on the date of mailing if mailed by any global express earner service that requires the recipient to sign the
documents demonstrating the delivery of such notice or payment, or 

  

	 	25.1.4	 in the case of notices, if sent by email, on the date the recipient acknowledges having received that email by
either an email sent to the sender or by a notice delivered by another method in accordance with this section 25.1, provided that, automated replies and “read receipts” shall not be considered acknowledgement of receipt and any provision
of notice of breach or termination shall be send using certified mail or global express earner. 

  

	In the case of Licensee:	 TheRas, Inc. 

165 University Avenue, Suite 5 

Palo Alto, CA 94301 
 Attention:
Neil Kumar 
 Email: [***] 
 In the case of
The Regents: 
 For notices: 

Office of Innovation, Technology, and Alliances 

3333 California Street, Suite S-11 

San Francisco, CA 94143-1209 

(for express mail and deliveries use zip 94118) 

Attention: Director, Technology Management 

Referring to: UC Case No. [***] 

Email: [***] 
 For
remittance of payments: 
 Innovation Alliances and Services 

Attn: Accounts Receivable 

University of California 

Office of the President 
 1111
Franklin Street, 5th Floor 
 Oakland, CA 94607-5200 

Referring to: UC Case No. [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 31 

 26. ASSIGNABILITY 

 

	26.1	 The Licensee may assign or transfer this Agreement, without The Regents’ prior written consent, only in
the case of assignment or transfer to a third party that succeeds to (whether by purchase or otherwise) all or substantially all of Licensee’s business or assets relating to this Agreement, whether by Sale, merger, operation of law or
otherwise, provided that (a) such assignee or transferee promptly agrees to be bound by the terms and conditions of tins Agreement and signs The Regents’ standard substitution of party letter (attached here as Appendix A), (b) Licensee
gives The Regents of reasonably prompt notice, but not longer than [***] following such assignment, and (c) [***]. Any attempted assignment by Licensee other than in accordance with this Paragraph 26.1 will be null and void. This Agreement is
binding upon and will inure to the benefit of The Regents, its successors and assigns. 

 27. FORCE MAJEURE 

 

	27.1	 Except for the Licensee’s obligation to make any payments to The Regents hereunder, the parties shall not
be responsible for failure to perform due to the occurrence of any events beyond their reasonable control which render their performance impossible or onerous, including, but not limited to: accidents (environmental, toxic spill, etc.); acts of God;
biological or nuclear incidents; casualties; earthquakes; fires; Hoods; governmental acts; orders or restrictions; inability to obtain suitable and sufficient labor, transportation, fuel and materials; local, national or state emergency; power
failure and power outages; acts of terrorism; strike; and war. 

 28. GOVERNING LAWS; VENUE 

 

	28.1	 Choice of Law. THIS AGREEMENT WILL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE
OF CALIFORNIA, excluding any choice of law rales that would direct the application of the laws of another jurisdiction and without regard to which party drafted particular provisions of this Agreement, but the scope and validity of any patent or
patent application will be governed by the applicable laws of the country of such patent or patent application. 

  

	28.2	 Venue. Any legal action brought by the parties hereto relating to this Agreement will be conducted in
San Francisco, California. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 32 

 29. GOVERNMENT APPROVAL OR REGISTRATION 

 

	29.1	 If this Agreement or any associated transaction is required by the law of any nation to be either approved or
registered with any governmental agency, the Licensee will assume all legal obligations to do so. The Licensee will notify The Regents if it becomes aware that this Agreement is subject to a United States or foreign government reporting or approval
requirement. The Licensee will make all necessary filings and pay all costs including fees, penalties and all other out-of-pocket costs associated with such reporting or
approval process. 

 30. COMPLIANCE WITH LAWS 

 

	30.1	 The Licensee shall comply with all applicable international, national, state, regional and local laws and
regulations in performing its obligations hereunder and in its use, manufacture, Sale or import of the Licensed Products, Licensed Services or practice of the Licensed Method. The Licensee will observe all applicable United States and foreign laws
with respect to the transfer of Licensed Products and related technical data and the provision of Licensed Services to foreign countries, including, without limitation, the International Traffic in Arms Regulations (ITAR) and the Export
Administration Regulations. The Licensee shall manufacture Licensed Products and practice the Licensed Method in compliance with applicable government importation laws and regulations of a particular country for Licensed Products made outside the
particular country in which such Licensed Products are used, Sold or otherwise exploited. 

 31. CONFIDENTIALITY

  

	31.1	 Confidential Information. The Licensee and The Regents will treat and maintain the other party’s
proprietary business, patent prosecution, software, engineering drawings, process and technical information and other proprietary information, including the negotiated terms of this Agreement and any progress reports and royalty reports and any
sublicense agreement issued pursuant to this Agreement (“Proprietary Information”) in confidence using at least the same degree of care as the receiving party uses to protect its own proprietary information of a like nature from the date
of disclosure until five (5) years after the termination or expiration of this Agreement. Proprietary Information can be written, oral, or both. This confidentiality obligation will apply to the information defined as “Data”
under the Secrecy Agreement and such Data will be treated as Proprietary Information hereunder. 

  
 33 

	31.2	 The Licensee and The Regents may use and disclose Proprietary Information to their employees, agents,
consultants, contractors and, in the case of the Licensee, its sublicensees, provided that such parties are bound by a like duty of confidentiality as that found in this Article 31 (Confidentiality). Notwithstanding anything to the contrary
contained in this Agreement, The Regents may release this Agreement, including any terms contained herein and information regarding payments or other income received in connection with this Agreement to the inventors, senior administrative officials
employed by The Regents and individual Regents upon their request. If such release is made, then The Regents will request that such terms be kept in confidence in accordance with the provisions of this Article 31 (Confidentiality). In addition,
notwithstanding anything to the contrary in this Agreement, if a third party inquires whether a license to Patent Rights is available, then The Regents may disclose the existence of this Agreement and the extent of the grant in Articles, 2
(Grant) and 3 (Sublicenses) and related definitions to such third party, but will not disclose the name of the Licensee unless the Licensee has already made such disclosure publicly. 

 

	31.3	 Limitations. Nothing contained herein will restrict or impair, in any way, the right of the Licensee or
The Regents to use or disclose any Proprietary Information: 

  

	 	31.3.1	 that recipient can demonstrate by written records was previously known to it prior to its disclosure by the
disclosing party; 

  

	 	31.3.2	 that recipient can demonstrate by written records is now, or becomes in the future, public knowledge other than
through acts or omissions of recipient; 

  

	 	31.3.3	 that recipient can demonstrate by written records was obtained lawfully and without restrictions on the
recipient from sources independent of the disclosing party; and 

  

	 	31.3.4	 that The Regents is required to disclose pursuant to the California Public Records Act or other applicable law.

 The Licensee or The Regents also may disclose Proprietary Information that is required to be disclosed (i) to a
governmental entity or agency in connection with seeking any 

  
 34 

 
governmental or regulatory approval, governmental audit, regulatory requirement (including any regulation promulgated by any securities exchange) or other governmental contractual requirement or
(ii) by law, provided that the recipient uses reasonable efforts to give the party owning the Proprietary Information sufficient notice of such required disclosure to allow the party owning the Proprietary Information reasonable opportunity to
object to, and to take legal action to prevent, such disclosure. Nothing in this Agreement will be construed to prevent The Regents from reporting de-identified raw terms of the Agreement as part of a larger
database. 
  

	31.4	 Return of Information. Upon termination of this Agreement, the Licensee and The Regents will destroy or
return any of the disclosing party’s Proprietary Information in its possession within [***] following the termination of this Agreement and provide each other with prompt written notice that such Proprietary Information has been returned or
destroyed. Each party may, however, retain one copy of such Proprietary Information for archival purposes in non-working files. 

32. MISCELLANEOUS 
  

	32.1	 Appendices. This Agreement includes the attached Appendix A. 

 

	32.2	 Headings. The headings of the several sections are inserted for convenience of reference only and are
not intended to be a part of or to affect the meaning or interpretation of this Agreement. 

  

	32.3	 Binding Agreement. This Agreement is not binding on the parties until it has been signed below on behalf
of each party. It is then effective as of the Effective Date. 

  

	32.4	 Amendments. No amendment or modification of this Agreement is valid or binding on the parties unless
made in writing and signed on behalf of each party. 

  

	32.5	 Waiver. No waiver by either party of any breach or default of any of the agreements contained herein
will be deemed a waiver as to any subsequent and/or similar breach or default. 

  

	32.6	 Entire Agreement. This Agreement embodies the entire understanding of the parties and supersedes all
previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter hereof. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 35 

	32.7	 Invalidity. In case any of the provisions contained in this Agreement is held to be invalid, illegal or
unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provisions of this Agreement and this Agreement will be construed as if such invalid, illegal or unenforceable provisions had never been
contained in it. 

  

	32.8	 Independent Contractors. In performing their respective duties under this Agreement, each of the parties
will be operating as an independent contractor. Nothing contained herein will in any way constitute any association, partnership, or joint venture between the parties hereto, or be construed to evidence the intention of the parties to establish any
such relationship. Neither party will have the power to bind the other party or incur obligations on the other party’s behalf without the other patty’s prior written consent. 

 

	32.9	 Counterparts. This Agreement may be executed in one or more counterparts, each of which together shall
constitute one and the same Agreement. For purposes of executing this Agreement, a facsimile (including a PDF image delivered via email) copy of this Agreement, including the signature pages, will be deemed an original. The parties agree that
neither party will have any rights to challenge the use or authenticity of a counterpart of this Agreement based solely on that its signature, or the signature of the other party, on such counterpart is not an original signature.

  

	32.10	 Execution. The terms and conditions of this Agreement shall be considered by The Regents to be withdrawn
from the Licensee’s consideration and the Agreement itself to be null and void, unless this Agreement is executed by both The Regents and the Licensee within thirty (30) days of when the execution copy is circulated for signatures.

  
 36 

 IN WITNESS WHEREOF, both The Regents and the Licensee have executed this Agreement by their respective and
duly authorized officers on the day and year written. 
  

									
	THERAS, INC.	 		 	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
					
	By:	 	 /s/ Neil Kumar
	 		 	By:	 	 /s/ Karin Immergluck

		 	(Signature)	 		 		 	(Signature)
					
	Name:	 	 Neil Kumar
	 		 	Name:	 	 Karin Immergluck

		 	(Please Print)	 		 		 	(Please Print)
					
	Title:	 	 CEO
	 		 	Title:	 	 Executive Director

					
	Date:	 	 September 28, 2016
	 		 	Date:	 	 September 30, 2016

  
 37 

 APPENDIX A: CONSENT TO SUBSTITUTION OF PARTY 

UC Case Nos. SF2015-143 

This substitution of parties (“Agreement”) is effective this
             day of             , 20    , among The Regents of the University of California (“The
Regents”), a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 and acting through its Office of Innovation, Technology, and Alliances, University of
California San Francisco (“UCSF”), 3333 California Street, Suite S-11, San Francisco, California 94143; [licensee name] (“XXX”), a         
corporation, having a principal place of business                     ; and [new licensee name] [(“YYY”)] a
                     corporation, having a principal place of business at
                    . 
 BACKGROUND 

A.    The Regents and [XXX] entered into a License Agreement effective
                     (UC Control No.
            -    -        ), entitled
                     (“License Agreement”), wherein XXX was granted certain rights. 

B.    [XXX] desires that [YYY] be substituted as Licensee (defined in the License Agreement) in place of [XXX], and The
Regents is agreeable to such substitution. 
 C.    [YYY] has read the License Agreement and agrees to abide by its
terms and conditions. 
 The parties agree as follows: 

1.    [YYY] assumes all liability and obligations under the License Agreement and is bound by all its terms in all respects as if it were
the original Licensee of the License Agreement in place of XXX. 
 2.    [YYY] is substituted for [XXX], provided that [YYY] assumes all
liability and obligations under the License Agreement as if [YYY] were the original party named as Licensee as of the effective date of the License Agreement. 

3.    The Regents releases [XXX] from all liability and obligations under the License Agreement arising before or after the effective date
of this Agreement. 

  
 38 

 The parties have executed this Agreement in triplicate originals by their respective
authorized officers on the following day and year. 
  

									
	[XXX] LICENSEE	 		 	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
					
	By:	 	  
	 		 	By:	 	
                     
                    

		 	(Signature)	 		 		 	
					
	Name:	 	  
	 		 	Name:	 	  

		 	(Please print)	 		 		 	
					
	Title:	 	  
	 		 	Title:	 	  

					
	Date:	 	  
	 		 	Date:	 	  

  

			
	[YYY] COMPANY
		
	By:	 	  

		 	(Signature)
		
	Name:	 	  

		 	(Please print)
		
	Title:	 	  

		
	Date:	 	  

  
 39 

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and
(ii) would be competitively harmful if publicly disclosed. 

 FIRST AMENDMENT 

to the 
 Exclusive License Agreement

 Effective September 28, 2016 

Between 
 THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA 
 and 

THERAS, INC. 
 Effective January 10, 2017,
(the “First Amendment Effective Date”) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (“THE REGENTS”), a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California
946075200 and acting through its Office of Innovation, Technology, and Alliances, University of California San Francisco (“UCSF”), 3333 California Street, Suite S-l 1, San Francisco, CA 94143 and
TheRas, Inc., a Delaware corporation and a subsidiary of BridgeBio, LLC, having a principal place of business at 165 University Avenue, Suite 5, Palo Alto, CA 94301 (“LICENSEE”), agree as follows: 

 

	1.	 BACKGROUND 

 

	 	1.1.	 THE REGENTS and LICENSEE are parties to a License Agreement effective September 28, 2016 with UC
Agreement Control No. 2017-03-0138 (“Original Agreement”) for “Covalent Modification on CAAX- box Cysteine of K-Ras 4B Using Tethering Compounds” as described in UC Case No.
[***]. 

  

	 	1.2.	 THE REGENTS and LICENSEE wish to amend the Original Agreement for the purpose of updating the PCT Application
Number in the Original Agreement. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 1 

	2.	 AMENDMENTS 

 

	 	2.1.	 Delete the table in Paragraph 1.11 and replace with the following: 

 

					
	 UC Case Number
	  	 PCT Application Number
	  	 Filing or Issue Date

	[***]	  	[***]	  	[***]

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 2 

 All other terms and conditions of the Original Agreement will remain in full force and effect. 

IN WITNESS WHEREOF, the parties hereto have executed these presents by their duly authorized officers or representatives as of the dates below: 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 
  

			
	By	 	 /s/ Sunita Rajdev

		
	Name	 	 Sunita Rajdev, Ph.D.

		
	Title	 	 Associate Director, Technology Management Innovation, Technology & Alliances UCSF

		
	Date	 	 1/17/17

 THERAS, INC. 
  

			
	By	 	 /s/ Neil Kumar

		
	Name	 	 Neil Kumar

		
	Title	 	 CEO

		
	Date	 	 1/12/2017

  
 3 

	[***]	 Certain information in this document has been omitted from this exhibit because it is both (i) not
material and (ii) would be competitively harmful if publicly disclosed. 

 SECOND AMENDMENT 

to the 
 Exclusive License
Agreement 
 Effective September 28, 2016 

Between 
 THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA 
 and 

THERAS, INC. 
 Effective
                    , (the “Second Amendment Effective Date”) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (“THE REGENTS”), a
California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 and acting through its Office of Technology Management, University of California San Francisco
(“UCSF”), 3333 California Street, Suite S-l 1, San Francisco, CA 94143 and TheRas, Inc., a Delaware corporation, having a principal place of business at 165 University Avenue, Suite 5, Palo Alto, CA
94301 (“LICENSEE”), agree as follows: 
  

	1.	 BACKGROUND 

 

	 	1.1	 THE REGENTS and LICENSEE are parties to a License Agreement effective September 28, 2016 with UC Agreement
Control No. 2017-03-0138 (“Original Agreement”) for “Covalent Modification on CAAX- box Cysteine of K-Ras 4B Using Tethering Compounds” as described in UC Case No. SF2015-143 and a first subsequent amendment with an
effective date of January 10, 2017 (the “First Amendment”). 

  

	 	1.2	 THE REGENTS and LICENSEE wish to amend the Original Agreement for the purpose adding additional patent rights
to “Phenylacetamide- and triazole-based covalent inhibitors targeting H95 in Kras” as described in UC Case No. [***] to the Original Agreement. 

  
 1 

	2.	 AMENDMENTS 

 

	 	2.1	 Background Paragraph A is hereby deleted and replaced with the following: 

“A. Certain inventions, generally characterized as “Covalent Modification on CAAX-box
Cysteine of K-Ras 4B Using Tethering Compounds” (UC Case Nos. [***] and Leidos Biomedical No. [***]) (collectively “Original Invention”), made in the course of research at UCSF and Leidos
Biomedical Research, Inc. (“Leidos”) by Drs. Frank P. McCormick, Stephan C. Gysin, Adam R. Renslo, and David Turner at UCSF and by Drs. Anna E. Maciag and Oleg Chertov of Leidos (collectively, the “Original Inventors”) and are
claimed in Patent Rights as defined below. Furthermore, certain inventions generally characterized as “Phenylacetamide- and triazole-based covalent inhibitors targeting H95 in Kras” as described in
UC Case No. [***] and Leidos Biomedical No. [***] (collectively the “Second Invention”), made in the course of research at UCSF by Drs. Frank P. McCormick, Adam R. Renslo, and Elizabeth D. Vo at UCSF and by Drs. Anna E. Maciag, David
Turner, and Marcin Dyba of Leidos Biomedical Research, Inc. (“Leidos”) (collectively, the “Second Inventor List”). The Original Invention and the Second Invention are collectively referred to as the “Invention”. The
Original Inventors and the Second Inventor List are collectively referred to as the “Inventors”. 
  

	 	2.2	 Background Paragraph C is hereby deleted and replaced with the following” 

“C. The Regents and Leidos have executed an Inter-Institutional Agreement (UC Control No. 2017-18-0104 ) with an effective date of August 22, 2016 and an hater-Institutional Agreement (UC Control
No. 2018-18-0028) with an effective date of July 10, 2017, both of which grant The Regents the right to license the Invention on behalf of both parties (the
“IIA”). 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 2 

	 	2.3	 The following is hereby added to the end of Background Paragraph D. 

“Furthermore, the Licensee and The Regents have executed a Second Secrecy Agreement (UC Control No. 2017-20-0376) with an effective date of March 28, 2017.” 
  

	 	2.4	 Paragraph 1.11 is hereby deleted and replaced with the following: 

“1.11 Patent Rights” means the Valid Claims of, to the extent assigned to or otherwise obtained by The Regents and/or Leidos, the
following United States patents and patent applications: 
  

					
	 UC Case Number
	  	PCT Application Number	  	Filing or Issue Date
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]

 Patent Rights shall further include the Valid Claims of, to the extent assigned to or otherwise obtained by
The Regents and/or Leidos, the corresponding foreign patents and patent applications and any reissues, extensions, substitutions, continuations, divisions, and
continuation-in-part applications (but only those Valid Claims in the
continuation-in-part applications that are entirely supported in the specification and entitled to the priority date of the parent application). Further, The Regents
agrees that it will not file or prosecute additional patent applications, outside the scope of the Patent Rights, based on the invention disclosure existing as of the Effective Date of the Original Agreement that is identified as UC Case No. [***]
and Leidos Biomedical No. [***] or existing as of the Second Amendment Effective Date that is identified as UC Case No. [***] and Leidos Biomedical No. [***]. For the avoidance of doubt, this definition of Patent Rights excludes any rights in and to
Option Inventions, except as provided under Article 4.” 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 3 

	 	2.5	 Paragraph 7.1 is hereby deleted and replaced with the following: 

 

	 	“7.1	 The Licensee will also pay to The Regents a license maintenance fee as follows for UC Case No. SF2015-143: 

  

	 	7.1.1	 [***] on [***]. 

  

	 	7.1.2	 [***] beginning on the [***] and continuing annually on each subsequent anniversary of the Effective Date of
the Original Agreement 

  

	 	7.1.3	 Notwithstanding the payment obligations set forth in Section 7.1.1 and 7.1.2, license maintenance fees set
forth in Paragraphs 7.1.1 and 7.1.2 are not due on any anniversary of the Effective Date of the Original Agreement if on that date, the Licensee is Selling or otherwise exploiting Licensed Products or Licensed Services covered by Patent Rights under
UC Case No. [***] and is paying an Earned Royalty to The Regents on the Net Sales of such Licensed Product or Licensed Service. 

  

	 	7.2	 The Licensee will also pay to The Regents a license maintenance fee as follows for UC Case No. SF2017-066: 

  

	 	7.2.1	 [***] on [***]. 

  

	 	7.2.2	 [***] beginning on the [***] and continuing annually on each subsequent anniversary of the Second Amendment
Effective Date. 

  

	 	7.2.3	 Notwithstanding the payment obligations set forth in Section 7.2.1 and 7.2.2, license maintenance fees set
forth in Paragraphs 7.2.1 and 7.2.2 are not due on any anniversary of the Second Amendment Effective Date if on that date, the Licensee is Selling or otherwise exploiting Licensed Products or Licensed Services covered by Patent Rights under UC Case
No. [***] and is paying an Earned Royalty to The Regents on the Net Sales of such Licensed Product or Licensed Service. 

  

	 	7.3	 The license maintenance fees set forth above in Paragraphs 7.1 and 7.2 are
non-refundable and are not an advance or otherwise creditable against any royalties or other payments required to be paid under the terms of this Agreement. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 4 

	 	2.6	 The following Paragraph is hereby added to the end of Paragraph 8.1: 

 

	 	“8.1.4.	 Licensee shall report to The Regents which Patent rights are included in each Sublicense. If the patent rights
from both cases (i.e., UC Case Nos. [***] and [***]) are being sublicensed, then Sublicense Fees due in accordance with the foregoing shall be split and distributed evenly between the cases. If only one case is being sublicensed, then the Sublicense
Fees shall be distributed to that case only.” 

  

	 	2.7	 The follow Paragraph is hereby added to the end of Paragraph 9.1: 

 

	 	“9.1.4	 Licensee shall indicate to The Regents in royalty reports which Patent Rights corresponds to the royalty
payments for which Licensed Products.” 

  

	 	2.8	 The following Paragraphs are hereby added to the end of Article 10: 

 

	 	“10.4	 If the Patent Rights from both cases (i.e., UC Case Nos. [***] and [***]) cover a Licensed Product that
triggers a Milestone Payment, then Milestone Payments due in accordance with the foregoing shall be [***]. If such Licensed Product is only covered by patent rights from one case, then the Milestone Payments shall be [***]. 

 

	 	10.5.	 Licensee shall indicate to The Regents in progress reports which Patent Rights corresponds to which Licensed
Product that triggers a Milestone Payment.” 

  

	 	2.9	 Paragraph 11.1.1 is hereby deleted and replaced with the following: 

 

	 	“11.1.1	 N shall be the number equivalent of the number of shares equal to [***] of the then-outstanding shares of
common stock of Licensee (assuming full conversion of all then-outstanding preferred stock and convertible securities and full exercise of any then-outstanding options and warrants) calculated on an
as-converted basis as of immediately after the closing of a Licensee Financing (as defined in Paragraph 11.6 below); and” 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 5 

	 	2.10	 Paragraph 11.7 is hereby deleted and replaced with the following: 

 

	 	“11.7	 Notwithstanding the above, in the event that a Change of Control Transaction or IPO occurs prior to the
Licensee Financing date, the Indexed Milestone Payment shall be equal to the greater of a) N times $P, where $P is determined as in 11.1.2.2 above, and where N equals [***] of the then-outstanding shares of Licensee (assuming full conversion of all
then-outstanding convertible securities and full exercise of any then-outstanding options and warrants) immediately after the closing of a Change of Control Transaction, and (b) one million eight hundred thousand dollars ($1,800,000).”

  

	 	2.11	 Paragraph 13.3 is hereby deleted and replaced with the following: 

 

	 	“13.3	 The Licensee will: 

  

	 	13.3.1	 [***] 

  

	 	13.3.2	 [***] 

  

	 	13.3.3	 [***] 

  

	 	13.3.4	 With respect to one Licensed Product covered by Patent Rights described in UC Case No. [***]:

  

	 	            [***]	 

The Regents recognizes that there are uncertainties associated with the development of therapeutic products and the regulatory process
required by the FDA (and Foreign regulatory authorities that are equivalent to the FDA), and that it may be necessary from time to time to amend one or more of the milestones under Paragraphs 13.3.3.2 through 13.3.3.7 and Paragraphs 13.3.4.1 through
13.3.4.7. Accordingly, if Licensee is unable to meet one or more of such specified milestones and Licensee demonstrates to The Regents, based on the Regents’ reasonable, objective, good faith assessment of Licensee’s demonstration and
supporting documentation, that Licensee has used and is using Licensee’s diligent efforts (with supporting documentation) to meet such milestone and [***] then upon submission in writing by Licensee to The Regents of the aforementioned

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 6 

 
diligent efforts and a plan to overcome such regulatory hurdles, The Regents will extend the deadline for each such milestone under Paragraphs 13.3.3.2 through 13.3.3.7 and/or Paragraphs 13.3.4.1
through 13.3.4.7 for a [***] provided Licensee also has paid to The Regents a fee, for each such extension, [***]. An extension of one milestone in Paragraph 13.3.3 will extend all remaining milestones in Paragraph 13.3.3 by the same extension time
period, and an extension of one milestone in Paragraph 13.3.4 will extend all remaining milestones in Paragraph 13.3.4. and 
  

	 	13.3.5	 use commercially reasonable efforts to fill the market demand for Licensed Products and Licensed Services
following commencement of marketing at any time. 

  

	 	2.12	 Paragraph 25.1.4 is hereby deleted and replaced with the following: 

“in the case of notices, if sent by email, on the date the recipient acknowledges having received that email by either an email sent to
the sender or by a notice delivered by another method in accordance with this section 25.1, provided that, automated replies and “read receipts” shall not be considered acknowledgement of receipt and any provision of notice of breach or
termination shall be send using certified mail or global express carrier. 
  

			
	 In the case of Licensee:
	  	 TheRas, Inc.

		  	 165 University Avenue, Suite 5

		  	 Palo Alto, CA 94301

		  	 Attention: Neil Kumar

		  	 Email: [***]

 In the case of The Regents: 

For notices: 

Office of Innovation, Technology, and Alliances 

3333 California Street, Suite S-11 

San Francisco, CA 94143-1209 

(for express mail and deliveries use zip 94118) 

Attention: Director, Technology Management 

Referring to: UC Case Nos. [***] 

Email: [***] 
 For
remittance of payments: 
 Innovation Alliances and Services 

Attn: Accounts Receivable 

University of California 

Office of the President 
 1111
Franklin Street, 5th Floor 
 Oakland, CA 94607-5200 

Referring to: UC Case Nos. [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 7 

	3.	 FEES 

  

	 	3.1	 Amendment Issue Fee: the Licensee will pay to The Regents an amendment license issue fee of [***] within [***]
of the Second Amendment Effective Date. This fee is non-refundable, non-cancelable and is not an advance or otherwise creditable against any royalties or other payments required to be paid under the terms of this Second Amendment or Original
Agreement. 

  

	4.	 Miscellaneous 

 

	 	4.1	 All other terms and conditions of the Original Agreement will remain in full force and effect.

  

	 	4.2	 This Second Amendment may be executed in one or more counterparts, each of which together shall constitute one
and the same Agreement. For purposes of executing this Agreement, a facsimile (including a PDF image delivered via email) copy of this Agreement, including the signature pages, will be deemed an original. The parties agree that neither party will
have any rights to challenge the use or authenticity of a counterpart of this Agreement based solely on that its signature, or the signature of the other party, on such counterpart is not an original signature. 

[signature page follows] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 8 

 IN WITNESS WHEREOF, the parties hereto have executed these presents by their duly authorized officers or
representatives as of the dates below: 
 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 

 

			
	By	 	 /s/ Sunita Rajdev

	Name	 	 Sunita Rajdev

	Title	 	 Associate Director, Technology Management Innovation, Technology & Alliances UCSF

	Date	 	 8-10-17

	
	THERAS, INC.
		
	By	 	 /s/ Cameron Turtle

	Name	 	 Cameron Turtle

	Title	 	 VP, Business Development and Operations

	Date	 	 8/8/2017

  
 9 

	 	[***]	 Certain information in this document has been omitted from this exhibit because it is both (i) not
material and (ii) would be competitively harmful if publicly disclosed. 

 THIRD AMENDMENT 

to the 
 Exclusive License
Agreement 
 Effective September 28, 2016 

Between 
 THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA 
 and 

THERAS, INC. 
 Effective September 7th. 2018, (the “Third Amendment Effective Date”) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (“THE REGENTS”), a California corporation, having its statewide administrative offices
at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 and acting through its Office of Technology Management, University of California San Francisco (“UCSF”), 600 16th Street, Suite
S-272, San Francisco, CA 94143and TheRas, Inc., a Delaware corporation, having a principal place of business at 421 Kipling Street, Palo Alto, CA 94301 (“LICENSEE”), agree as follows: 

 

	1.	 BACKGROUND 

 

	 	1.1.	 THE REGENTS and LICENSEE are parties to a License Agreement effective September 28, 2016 with UC Agreement
Control No. 2017-03-0138 (“Original Agreement”) for “Covalent Modification on CAAX- box Cysteine of K-Ras 4B
Using Tethering Compounds” as described in UC Case No. [***], a first subsequent amendment with an effective date of January 10, 2017 (the “First Amendment”), and a subsequent amendment with an effective date of August 10,
2017 (the “Second Amendment”). 

  
 1 

	 	1.2.	 THE REGENTS and LICENSEE wish to amend the Original Agreement for the purpose adding additional patent rights
to “Sulfonamide-based modulators of KRAS4b with enhanced biochemical and biological activity over analogous amides” as described in UC Case No. [***] to the Original Agreement. 

 

	2.	 AMENDMENTS 

 

	 	2.1.	 Background Paragraph A is hereby deleted and replaced with the following: 

“A. Certain inventions, generally characterized as “Covalent Modification on CAAX-box
Cysteine of K-Ras 4B Using Tethering Compounds” (UC Case Nos. [***] and Leidos Biomedical No. [***]) (collectively “Original Invention”), made in the course of research at UCSF and Leidos
Biomedical Research, Inc. (“Leidos”) by Drs. Frank P. McCormick, Stephan C. Gysin, Adam R. Renslo, and David Turner at UCSF and by Drs. Anna E. Maciag and Oleg Chertov of Leidos (collectively, the “Original Inventors”) and are
claimed in Patent Rights as defined below. Furthermore, certain inventions generally characterized as “Phenylacetamide- and triazole-based covalent inhibitors targeting H95 in Kras” as described in
UC Case No. [***] and Leidos Biomedical No. [***] (collectively the “Second Invention”), made in the course of research at UCSF by Drs. Frank P. McCormick, Adam R. Renslo, and Elizabeth D. Vo at UCSF and by Drs. Anna E. Maciag, David
Turner, and Marcin Dyba of Leidos Biomedical Research, Inc. (“Leidos”) (collectively, the “Second Inventor List”). The Original Invention and the Second Invention are collectively referred to as the “Initial Invention
Set”. Moreover, certain inventions generally characterized as “Sulfonamide-based modulators of KRAS4b with enhanced biochemical and biological activity over analogous amides” as described in UC Case No [***] (the “Subsequent
Invention”), were made in the course of research at UCSF by Drs. Francis P McCormick and Adam R Renslo at UCSF, by Drs. Anna E. Maciag, David M Turner, Christopher Brassard, Vandana Kumari, and Marcin Dyba at Leidos, and

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 2 

 
by Drs. Matthew Duncton and Eddie Low, of Licensee (“Third Inventor List”). The Initial Invention Set and the Subsequent Invention are collectively referred to as the
“Invention”. The Original Inventors, the Second Inventor List, and the Third Inventor List are collectively referred to as the “Inventors”. 
  

	 	2.2.	 Background Paragraph C is hereby deleted and replaced with the following” 

“C. The Regents and Leidos have executed an Inter-Institutional Agreement (UC Control No. 2017-18-0104 ) with an effective date of August 22, 2016 and an Inter-Institutional Agreement (UC Control
No. 2018-18-0028) with an effective date of July 10, 2017, both of which grant The Regents the right to license the Initial Invention Set on behalf of both
parties (the “IIA”). 
  

	 	2.3.	 The following is hereby added to the end of Background Paragraph D. 

“Furthermore, the Licensee and The Regents have executed a third Secrecy Agreement (UC Control No. 2018-20-0107) with an effective date of October 12, 2017.” 
  

	 	2.4.	 Paragraph 1.11 is hereby deleted and replaced with the following: 

“1.11 Patent Rights” means the Valid Claims of the following: 

 

	 	(a)	 to the extent assigned to or otherwise obtained by The Regents and/or Leidos, the following United States
patents and patent applications, herein as defined as “Initial Patent Rights”: 

  

					
	 UC Case Number
	  	Application Number	 	Filing or Issue Date
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 3 

 Initial Patent Rights shall further include the Valid Claims of, to the extent assigned to
or otherwise obtained by The Regents and/or Leidos, the corresponding foreign patents and patent applications and any reissues, extensions, substitutions, continuations, divisions, and
continuation-in-part applications (but only those Valid Claims in the
continuation-in-part applications that are entirely supported in the specification and entitled to the priority date of the parent application). Further, The Regents
agrees that it will not file or prosecute additional patent applications, outside the scope of the Patent Rights, based on the invention disclosure existing as of the Effective Date of the Original Agreement that is identified as UC Case No. [***]
and Leidos Biomedical No. [***] or existing as of the Second Amendment Effective Date that is identified as UC Case No. [***] and Leidos Biomedical No. [***]. For the avoidance of doubt, this definition of Patent Rights excludes any rights in and to
Option Inventions, except as provided under Article 4.” 
  

	 	(b)	 to the extent assigned to or otherwise obtained by The Regents, the following United States patents and patent
applications, herein defined as the “Subsequent Patent Rights”: 

  

					
	 UC Case Number
	  	U.S. Provisional Patent
Application Number	 	Filing Date
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]

 Subsequent Patent Rights shall further include the Valid Claims of, to the extent assigned to or otherwise
obtained by The Regents, the corresponding foreign patents and patent applications and any reissues, extensions, substitutions, continuations, divisions, and
continuation-in-part applications (but only those Valid Claims in the
continuation-in-part applications that are entirely supported in the specification and entitled to the priority date of the parent application). For

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 4 

 
the avoidance of doubt, Subsequent Patent Rights shall further include provisional or nonprovisional applications filed within the Paris convention year with claims to additional compounds or sub-genera that fall within the scope of the genus described in the Subsequent Patent Rights existing as of the Third Amendment Effective Date, provided that (1) such applications are conceived and reduced to
practice by Dr. Frank McCormick and/or Dr. Adam Renslo (including together with inventors at Leidos and/or Licensee), (2) such applications are assigned to or otherwise obtained by only The Regents, Leidos, and Licensee, and
(3) within sixty (60) days of the filing of such patent applications, the parties amend in writing the table in this Section 2.4(b). 

For the avoidance of doubt, Patent Rights shall include both the Initial Patent Rights and the Subsequent Patent Rights. For the avoidance of
doubt, this definition of Patent Rights excludes any rights in and to Option Inventions, except as provided under Article 4.” 
  

	 	2.5.	 Paragraph 7.1 is hereby deleted and replaced with the following: 

 

	 	“7.1	 The Licensee will also pay to The Regents a license maintenance fee as follows for UC Case No. [***]:

  

	 	7.1.1	 [***] on both [***] 

  

	 	7.1.2	 [***] beginning on the [***] and continuing annually on each subsequent anniversary of the Effective Date of
the Original Agreement 

  

	 	7.1.3	 Notwithstanding the payment obligations set forth in Section 7.1.1 and 7.1.2, license maintenance fees set
forth in Paragraphs 7.1.1 and 7.1.2 are not due on any anniversary of the Effective Date of the Original Agreement if on that date, the Licensee is Selling or otherwise exploiting Licensed Products or Licensed Services covered by Patent Rights under
UC Case No. [***] and is paying an Earned Royalty to The Regents on the Net Sales of such Licensed Product or Licensed Service. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 5 

	 	7.2	 The Licensee will also pay to The Regents a license maintenance fee as follows for UC Case No. [***]:

  

	 	7.2.1	 [***] 

  

	 	7.2.2	 [***] and continuing annually on each subsequent anniversary of the Second Amendment Effective Date.

  

	 	7.2.3	 Notwithstanding the payment obligations set forth in Section 7.2.1 and 7.2.2, license maintenance fees set
forth in Paragraphs 7.2.1 and 7.2.2 are not due on any anniversary of the Second Amendment Effective Date if on that date, the Licensee is Selling or otherwise exploiting Licensed Products or Licensed Services covered by Patent Rights under UC Case
No. [***] and is paying an Earned Royalty to The Regents on the Net Sales of such Licensed Product or Licensed Service. 

  

	 	7.3	 The Licensee will also pay to The Regents a license maintenance fee as follows for UC Case No. [***]:

  

	 	7.3.1	 [***] on both the [***]. 

 

	 	7.3.2	 [***] beginning on the [***] and continuing annually on each subsequent anniversary of the Third Amendment
Effective Date. 

  

	 	7.2.1	 Notwithstanding the payment obligations set forth in Section 7.3.1 and 7.3.2, license maintenance fees set
forth in Paragraphs 7.3.1 and 7.3.2 are not due on any anniversary of the Second Amendment Effective Date if on that date, the Licensee is Selling or otherwise exploiting Licensed Products or Licensed Services covered by Patent Rights under UC Case
No. [***] and is paying an Earned Royalty to The Regents on the Net Sales of such Licensed Product or Licensed Service. 

  

	 	7.3	 The license maintenance fees set forth above in Paragraphs 7.1, 7.2, and 7.3 are
non-refundable and are not an advance or otherwise creditable against any royalties or other payments required to be paid under the terms of this Agreement. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 6 

	 	2.6.	 The following Paragraph is hereby added to the end of Paragraph 8.1: 

 

	 	“8.1.4.	 Licensee shall report to The Regents which Patent rights are included in each Sublicense. If the patent rights
from more than one case is being sublicensed, then Sublicense Fees due in accordance with the foregoing shall be [***]. If only one case is being sublicensed, then the Sublicense Fees shall be distributed [***].” 

 

	 	2.7.	 The follow Paragraph is hereby added to the end of Paragraph 9.1: 

 

	 	“9.1.4	 Licensee shall indicate to The Regents in royalty reports which Patent Rights corresponds to the royalty
payments for which Licensed Products.” 

  

	 	2.8.	 The following Paragraphs are hereby added to the end of Article 10: 

 

	 	“10.4	 If the Patent Rights from more than one case cover a Licensed Product that triggers a Milestone Payment, then
Milestone Payments due in accordance with the foregoing shall be [***]. If such Licensed Product is only covered by patent rights from one case, then the Milestone Payments shall be [***]. 

 

	 	10.5.	 Licensee shall indicate to The Regents in progress reports which Patent Rights corresponds to which Licensed
Product that triggers a Milestone Payment.” 

  

	 	2.9.	 Paragraph 13.3 is hereby deleted and replaced with the following: 

 

	 	“13.3	 The Licensee will: 

  

	 	13.3.1	 [***] 

  

	 	13.3.2	 [***] 

  

	 	13.3.3	 [***] 

  

	 	13.3.4	 With respect to one Licensed Product covered by Patent Rights described in UC Case No. [***]:

  

	 	 	 [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 7 

	 	13.3.5	 With respect to one Licensed Product covered by Patent Rights described in UC Case No. [***]:

  

	 	 	 [***] 

The Regents recognizes that there are uncertainties associated with the development of therapeutic products and the regulatory process
required by the FDA (and Foreign regulatory authorities that are equivalent to the FDA), and that it may be necessary from time to time to amend one or more of the milestones under Paragraphs 13.3.3.2 through 13.3.3.7, Paragraphs 13.3.4.1 through
13.3.4.7, and Paragraphs 13.3.5.1 through 13.3.5.7. Accordingly, if Licensee is unable to meet one or more of such specified milestones and Licensee demonstrates to The Regents, based on the Regents’ reasonable, objective, good faith assessment
of Licensee’s demonstration and supporting documentation, that Licensee has used and is using Licensee’s diligent efforts (with supporting documentation) to meet such milestone and to [***], then upon submission in writing by Licensee to
The Regents of the aforementioned diligent efforts and a plan to overcome such regulatory hurdles, The Regents will extend the deadline for each such milestone under Paragraphs 13.3.3.2 through 13.3.3.7 and/or Paragraphs 13.3.4.1 through 13.3.5.7
for a maximum of [***] provided Licensee also has paid to The Regents a fee, for each such extension, [***]. An extension of one milestone in Paragraph 13.3.3 will extend all remaining milestones in Paragraph 13.3.3 by the same extension time
period, an extension of one milestone in Paragraph 13.3.4 will extend all remaining milestones in Paragraph 13.3.4, and an extension of one milestone in Paragraph 13.3.5 will extend all remaining milestones in Paragraph 13.3.5. 

and 
  

	 	13.3.5	 use commercially reasonable efforts to fill the market demand for Licensed Products and Licensed Services
following commencement of marketing at any time. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 8 

	 	2.10.	 Notwithstanding anything to the contrary in Paragraph 21.1, the following shall govern the Parties’
respective rights and obligations with respect to the filing, prosecution and maintenance of Initial Patent Rights and Subsequent Patent Rights: 

  

	 	“21.1	 Patent Prosecution. 

 

	 	21.1.1	 For Initial Patent Rights: As long as the Licensee has paid patent costs as provided for in this
Article, The Regents shall diligently endeavor to prosecute and maintain the United States and foreign patents comprising Regents’ Patent Rights using counsel of its choice. The Regents will provide the Licensee with copies of all relevant
documentation so that the Licensee will be informed of the continuing prosecution and may comment upon such documentation sufficiently in advance of any initial deadline for filing a response (and The Regents shall incorporate such comments when
appropriate and/or reasonable), provided, however, that if the Licensee has not commented upon such documentation in a reasonable time for The Regents to sufficiently consider the Licensee’s comments prior to a deadline with the relevant
government patent office, or The Regents must act to preserve the Patent Rights, The Regents will be free to respond without consideration of the Licensee’s comments, if any. The Licensee agrees to keep this documentation confidential. The
Regents’ counsel will take instructions only from The Regents, and all patents and patent applications under the Initial Patent Rights will be assigned solely to The Regents, and when applicable, Leidos. The Regents shall use all reasonable
efforts to amend any patent application to include claims reasonably requested by the Licensee to protect the products contemplated to be sold under this Agreement and to file and prosecute patents in foreign countries indicated by and [***].

  

	 	21.1.2	 For Subsequent Patent Rights: Licensee, with the input of The Regents and Leidos as outlined below, will
be the party having the first right to file, prosecute, extend and maintain, and shall be responsible for filing, prosecuting, extending and maintaining, in good faith, the United States

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 9 

	 	
and foreign patent application(s) encompassing the Subsequent Patent Rights using patent counsel selected by Licensee, provided that such patent counsel is reasonably acceptable to The Regents
and Leidos. The Regents hereby confirms that Licensee’s selection of Cooley LLP as its patent counsel is acceptable to The Regents as of the Third Amendment Effective Date. 

Licensee and its selected patent counsel shall be responsible for keeping The Regents and Leidos reasonably informed of such activities with
respect to the Subsequent Patent Rights. Specifically, Licensee will instruct its counsel to copy The Regents and Leidos on all communications regarding Subsequent Patent Rights and provide The Regents and Leidos with copies of all relevant
correspondence and filings with respect to the Subsequent Patent Rights so that The Regents and Leidos will be informed of the continuing prosecution and may comment upon such filings sufficiently (and [***] when practicable) in advance of any
initial deadline for filing a response. In the event Licensee inadvertently omits providing The Regents and Leidos with any such copy, Licensee shall do so or instruct its counsel to do so as soon as practical. In the event such omissions are
ongoing and persistent, then at any Party’s request, Licensee, The Regents and Leidos shall discuss in good faith to establish a process of communication to address such omission. Licensee agrees to take such timely comments into consideration
and shall advise if such comments are not incorporated into any filing. Licensee and The Regents will cooperate in the prosecution of Subsequent Patent Rights. 

Licensee shall use all reasonable efforts to amend any patent application to include claims reasonably requested by The Regents in the
Subsequent Patent Rights. The Regents and Licensee hereby acknowledge that Licensee, The Regents, and Leidos jointly own the Subsequent Patent Rights. Licensee shall not abandon or make inventorship changes on any

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 10 

 
patent applications jointly owned by The Regents without first consulting The Regents. If [***] chooses to abandon a patent application jointly owned by either The Regents and/or Leidos
Biomedical, [***] (in consultation with each other if both The Regents and Leidos are co-owners) have the right to take over the prosecution and maintenance of such patent application [***]. The obligations of
the Parties under this Agreement shall terminate to the extent applicable to the abandoned patent or patent application. Licensee shall promptly transfer any applicable documents necessary for The Regents and/or Leidos to continue the prosecution
and maintenance of such patents or patent applications. 
 The Regents shall not file any patent application claiming or disclosing solely
the Subsequent Invention or claiming priority to Subsequent Patent Rights unless Licensee decides to abandon the prosecution or maintenance of any Subsequent Patent Rights or breaches its obligation to notify The Regents of its decision to abandon
Subsequent Patent Rights (the “Notification Breach”). If The Regents wishes to file a patent application covering an aspect of the Subsequent Invention that is not already covered by the Subsequent Patent Rights (“New Subsequent
Invention”), The Regents shall notify Licensee in writing. If Licensee chooses not to file on such New Subsequent Invention, The Regents is free to file on such New Subsequent Invention. In addition, if the Regents notifies the Licensee of its
Notification Breach and Licensee does not cure such breach or resume or continue such prosecution or maintenance of such Subsequent Patent Rights after the earlier of [***] notice of such breach, or [***] before an applicable patent or patent
prosecution bar date, The Regents is then free to discuss in good faith with Leidos a plan to assume the prosecution and/or maintenance of such Subsequent Patent Rights and to carry out such plan. For the avoidance of doubt, provided that there are
jointly owned Subsequent Patent Rights, Licensee shall not file any patent application that claims or discloses an invention related to the Subsequent Invention or claims priority to Subsequent Patent Rights without having a good faith discussion
with The Regents and Leidos Biomedical first regarding the filing strategy and inventorship.” 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 11 

	 	2.11.	 Paragraph 25.1.4 is hereby deleted and replaced with the following: 

“in the case of notices, if sent by email, on the date the recipient acknowledges having received that email by either an email sent to
the sender or by a notice delivered by another method in accordance with this section 25.1, provided that, automated replies and “read receipts” shall not be considered acknowledgement of receipt and any provision of notice of breach or
termination shall be send using certified mail or global express carrier. 
  

					
	                	 	In the case of Licensee:        	  	TheRas, Inc.
		 		  	421 Kipling Street
		 		  	Palo Alto, CA 94301
		 		  	Attention: Neil Kumar
		 		  	Email: [***]

 In the case of The Regents: 

For notices: 

University of California, San Francisco 

Innovation Ventures, Office of Technology Management, Box 2142 

600 16th Street, Suite S272 

San Francisco, CA 94143 

(for Fed-Ex use postal code 94158) 

Attention: Director, Technology Management 

Referring to: UC Case Nos. [***] 

Email: [***] 

For remittance of payments: 

Innovation Alliances and Services 

Attn: Accounts Receivable 

University of California 

Office of the President 
 1111
Franklin Street, 5th Floor 
 Oakland, CA 94607-5200 

Referring to: UC Case Nos. [***] 
  

	3.	 FEES 

  

	 	3.1.	 Amendment Issue Fee: the Licensee will pay to The Regents an amendment license issue fee of [***] within [***]
of the Second Amendment Effective Date. This fee is 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 12 

	 	
non-refundable, non-cancelable and is not an advance or otherwise creditable against any royalties or other
payments required to be paid under the terms of this Second Amendment or Original Agreement. 

  

	4.	 Miscellaneous 

 

	 	4.1.	 All other terms and conditions of the Original Agreement will remain in full force and 

 

	 	4.2.	 This Agreement hereby supersedes the Memorandum of Understanding between The Regents, Licensee, and Leidos,
dated February 20, 2018. 

  

	 	4.3.	 This Second Amendment may be executed in one or more counterparts, each of which together shall constitute one
and the same Agreement. For purposes of executing this Agreement, a facsimile (including a PDF image delivered via email) copy of this Agreement, including the signature pages, will be deemed an original. The parties agree that neither party will
have any rights to challenge the use or authenticity of a counterpart of this Agreement based solely on that its signature, or the signature of the other party, on such counterpart is not an original signature. 

[signature page follows] 

  
 13 

 IN WITNESS WHEREOF, the parties hereto have executed these presents by their duly authorized officers or
representatives as of the dates below: 
 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 

 

			
	By	 	 /s/ Sunita Rajdev

	Name	 	 Sunita Rajdev

	Title	 	 Interim Executive Director

	Date	 	 9/10/18

	
	THERAS, INC.
		
	By	 	 /s/ Michael Henderson

	Name	 	 Michael Henderson

	Title	 	 CBO

	Date	 	 9/7/2018

  
 14EX-10.15

 Exhibit 10.15 

EXECUTION VERSION 

 

	[***]	 Certain information in this document has been omitted from this exhibit because it is both (i) not
material and (ii) would be competitively harmful if publicly disclosed. 

 COLLABORATION AND LICENSE
AGREEMENT 
 by and among 
 The
University of Texas M.D. Anderson Cancer Center, 
 The Board of Regents of the University of Texas System, 

And 
 PTP Pharmaceuticals, Inc.

 COLLABORATION AND LICENSE AGREEMENT 

This Agreement is effective as of March 3, 2017 (the “Effective Date”), by and among The Board of Regents
(“Board”) of The University of Texas System (“System”), The University of Texas M.D. Anderson Cancer Center, a member institution of System and an agency of the State of Texas, with offices at 1515 Holcombe Blvd.,
Houston, Texas 77030 (“MDACC”), and PTP Pharmaceuticals, Inc., a Delaware corporation located at 165 University Avenue, Suite #5, Palo Alto, CA 94301 (“Company”). Board, MDACC, and Company are each sometimes
referred to herein as a “Party” or collectively as the “Parties.” 
 RECITALS 

WHEREAS, MDACC is an institution of higher education and a comprehensive cancer research, treatment and prevention center; 

WHEREAS, Board is the owner of certain Licensed Technology and Company wishes to obtain an exclusive license under Board’s rights in the
Licensed Technology; 
 WHEREAS, in partial consideration for the issuance of [***] shares of common stock of Company to Board [***] set
forth in the Stock Purchase Agreement dated March 3, 2017 (the “Stock Purchase Agreement”), by and between Board and Company, Board has agreed to grant Company an exclusive license to the Licensed Technology; 

WHEREAS, in addition to granting and receiving the exclusive license mentioned above, Company and MDACC desire to engage in a collaboration
pursuant to which the Parties will collaborate in research and development of products covered by the Licensed Technology, using their respective technologies and expertise (“Collaboration”). 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the Parties hereto,
intending to be legally bound, hereby agree as follows: 
 ARTICLE 1 

DEFINITIONS 

1.1    “Affiliate” of a Party shall mean any entity which directly or indirectly controls, or is
controlled by, or is under common control with such Party. The term “control” as used herein means: (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled to vote
for the election of directors; or (b) the power to direct the management and policies of such entities. 

1.2    “Applicable Law” means the applicable laws, rules and regulations, including any rules,
regulations, guidelines or other requirements of Governmental Authorities (e.g., Regulatory Authorities), that may be in effect from time to time. Specifically and without limiting the foregoing, Applicable Law includes the Foreign Corrupt Practices
Act of 1977, as amended. 
 1.3    “Collaboration Technology” means all inventions or discoveries
(whether or not patentable or copyrightable) that are invented or discovered at MDACC, solely by a MDACC employee who is a member of IACS or jointly by such MDACC employee and an employee of Company, during the performance of MDACC Development
Activities. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 1 

 1.4    “Combination Product” shall mean any Licensed
Product sold or used in combination with one or more other products or processes which are not Licensed Products. 

1.5    “Commercialization” means the marketing, promotion, sale and/or distribution of a Licensed Product
in the Territory, including, without limitation, any post marketing surveillance and marketing and promotional activities conducted in preparation for Licensed Product launch. “Commercialize” has a correlative meaning. 

1.6    “Commercially Reasonable Efforts” means, with respect to a Party’s obligations under this
Agreement to Develop, manufacture or Commercialize a Licensed Product, the carrying out of such obligations or tasks with [***]. 

1.7    “Confidential Information” means any confidential or proprietary information disclosed or
otherwise made available by or on behalf of the disclosing party to the receiving party for the purposes of the Collaboration, whether in oral, visual, written electronic, or any other form. Information to which the receiving party gains access
during visits to the facilities of the disclosing party or its Affiliates shall also be deemed Confidential Information. For the avoidance of doubt, Confidential Information may include, but is not limited to: (a) data, know-how,
formulas, compositions, processes, documents, designs, sketches, photographs, plans, graphs, drawings or specifications; (b) chemical structures, amino/nucleic acid sequences, structural biology, or descriptions of any devices, cell lines or
molecular models; (c) clinical trial protocols, assays, services, studies, results, findings, inventions, ideas and other knowledge; or (d) finances, financial models, business plans and marketing plans, reports, customer lists or
pricing information. To the extent permitted by Applicable Laws, Confidential Information also includes the existence, terms and purpose contemplated by this Agreement, the terms of any other agreements being discussed by the parties related to the
Collaboration, as well as the fact that any such discussions are taking place with respect thereto. Confidential Information does not include information that: (v) is at the time of disclosure in the public domain; (w) comes
into the public domain through no fault of the receiving Party; (x) was at the time of disclosure known to the receiving Party prior to its disclosure by the disclosing Party; as evidenced by contemporaneous written documentation;
(y) is disclosed to the receiving Party by a third party who has a right to disclose and who is not under an obligation of nondisclosure; or (z) is independently developed by the receiving Party without reference to or use of
the Confidential Information, as evidenced by contemporaneous written records. 
 1.8    “Control” or
“Controlled” means, with respect to any Information or Patent Rights, possession (whether by ownership or license, other than pursuant to this Agreement), by a Party of the right to grant a license or sublicense without violating
the terms of any agreement with any Third Party. 
 1.9    “Develop” or “Development”
means all activities that relate to obtaining, maintaining or expanding Regulatory Approval of a Licensed Product. This includes: (a) nonclinical testing, toxicology, and clinical trials; (b) preparation, submission, review, and
development of data or information for the purpose of submission to a Governmental Authority to obtain, maintain and/or expand Regulatory Approval of a Licensed Product, and outside counsel, regulatory, and legal services related thereto; provided,
however, that Development shall exclude Commercialization and the building of commercial inventory of a Licensed Product. 

1.10    “FD&C Act” means the United States Federal Food, Drug and Cosmetic Act, as amended. 

1.11    “Field” shall mean all fields. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 2 

 1.12    “First Commercial Sale” means, with respect to
any Licensed Product in any country in the Territory, the first sale, transfer or disposition for value to an end user of that Licensed Product in that country after Regulatory Approval for the Licensed Product has been received in that country;
provided, that, the following will not constitute a First Commercial Sale: (a) any sale to an Affiliate or distributor (unless the Affiliate or distributor is the last entity in the distribution chain of the Licensed Product); (b) any sale or
transfer that restricts the use of the Licensed Product solely to use of the Licensed Product in clinical trials, pre-clinical studies or other research or Development activities; or (c) the disposal or
transfer of Licensed Products for a bona fide charitable purpose, including compassionate use or “named patient sales”. 

1.13    “FTE Cost” means, for any period, the FTE Rate multiplied by the number of FTEs used in such
period. 
 1.14    “FTE Rate” means the rate per full time equivalent (“FTE”). which
will be deemed to be [***] hours of research or development time per annum for FTEs engaged in the conduct of research and Development activities, which rate will be equal to [***] Dollars ($[***]). The above FTE Rate will be adjusted annually for
each calendar year after 2018 to be equal to the FTE Rate as of the Effective Date, or the preceding calendar year, as the case may be, plus a percentage increase equal to the percentage increase in the Consumer Price Index for all Urban Consumers,
as published by the U.S. Department of Labor, Bureau of Statistics. 
 1.15    “Governmental Authority”
means any multi-national, federal, state, local, municipal or other government authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal). 

1.16    “IACS” means the MDACC Institute for Applied Cancer Science. 

1.17    “IACS Improvements” means any and all Information and/or Patent Rights Controlled by Board that
is/are: (i) reasonably necessary for the research, development, manufacture or commercialization of a Licensed Product in the Field; (ii) invented or discovered at MDACC during the IACS Improvement Term by a MDACC employee
who is a member of IACS; and (iii) not Collaboration Technology. 
 1.18    “IACS Improvement
Term” means the time period beginning on the Effective Date and ending on the [***] anniversary of the Effective Date; provided, however, that if this Agreement terminates earlier than the foregoing date, then the IACS Improvement Term
shall terminate on the effective date of termination of this Agreement. 
 1.19    “IND” means:
(a) an Investigational New Drug Application as defined in the FD&C Act and applicable regulations promulgated thereunder by the FDA; or (b) the equivalent application to the equivalent Regulatory Authority in any other
regulatory jurisdiction, the filing of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction. 

1.20    “Information” means any data, results, and information of any type whatsoever, in any tangible or
intangible form, including, without limitation, know-how, trade secrets, practices, techniques, methods, processes, inventions, developments, specifications, formulations, formulae, materials or compositions of matter of any type or kind (patentable
or otherwise), software, algorithms, marketing reports, clinical and non-clinical study reports, regulatory submission documents and summaries, expertise, stability, technology, test data including
pharmacological, biological, chemical, biochemical, toxicological, and clinical test data, analytical and quality control data, stability data, studies and procedures. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 3 

 1.21    “Licensed Know-How” shall mean (a) the
inventions and discoveries set forth in the MDACC Invention Disclosure Report listed on Exhibit A and (b) all Information Controlled by Board, as of the Effective Date, that: (i) is reasonably necessary for the research, development,
manufacture or commercialization of a Licensed Product in the Field and (ii) was invented or discovered at MDACC before the Effective Date by a MDACC employee who is a member of IACS. 

1.22    “Licensed Patents” shall mean all Patent Rights Controlled by Board, as of the Effective Date,
that: (i) are reasonably necessary for the research, development, manufacture or commercialization of a Licensed Product in the Field and (ii) were invented or discovered at MDACC before the Effective Date by a MDACC employee who
was a member of IACS at the time of invention or discovery, including the patents and patent applications listed on Exhibit A. 

1.23    “Licensed Product” shall mean any product the composition, manufacture, use, sale, offer for sale
or import of which comprises or uses any Licensed Technology. 
 1.24    “Licensed Technology” shall
mean all Licensed Patents, Licensed Know-How, and IACS Improvements. 
 1.25    “Net Sales” [***]. 

1.26    “Company Know-How” shall mean all Information Controlled as of the Effective Date or thereafter
during the Term by Company that is reasonably necessary or useful for the research, development, manufacture or commercialization of a Product in the Field. 

1.27    “Company Patents” shall mean all Patent Rights Controlled as of the Effective Date or thereafter
during the Term by Company that are reasonably necessary or useful for the research, development, manufacture or commercialization of a Product in the Field. 

1.28    “Company Technology” shall mean all Company Know-How and Company Patents. 

1.29    “Non-Dilutive Financing” means any financing received by Company or a direct or indirect
subsidiary of Company that is not in exchange for equity securities of Company or a direct or indirect subsidiary of Company or any securities convertible into equity securities of the Company or a direct or indirect subsidiary of Company. 

1.30    “Patent Rights” shall mean: (a) any national, regional or international patent or patent
application, including any provisional patent application; (b) any patent application filed either from such a patent, patent application or provisional application or from an application claiming priority from any of these, including any
divisional, continuation, continuation-in-part (to the extent the claims of such continuations-in-part are entitled to claim priority to the aforesaid patents and/or
patent applications), provisional, converted provisional, and continued prosecution application; (c) any patent that has issued or in the future issues from any of the foregoing patent applications ((a) and (b)), including any utility model,
petty patent, design patent and certificate of invention; (d) any extension or restoration by existing or future extension or restoration mechanisms, including any revalidation, reissue, re-examination and extension (including any
supplementary protection certificate and the like) of any of the foregoing patents or patent applications ((a), (b) and (c)); and (e) any similar rights, including so-called pipeline protection, or any importation, revalidation,
confirmation or introduction patent or registration patent or patent of additions to any such foregoing patent application or patent. 

1.31    “Phase II Trial” shall mean a human clinical trial of a Licensed Product, the principal purpose
of which is the preliminary determination of efficacy and/or preliminary establishment of 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 4 

 
appropriate dose ranges for efficacy and safety in the target patient population and that would satisfy the requirements under 21 C.F.R. § 312.21(b) for the United States, as amended from
time to time, or the corresponding regulations for a comparable filing with a comparable regulatory authority in a country other than the United States. 

1.32    “Phase III Trial” means that portion of the United States Food and Drug Administration approval
process in which expanded clinical trials are conducted to gather additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the Licensed Product, as more specifically defined under 21
C.F.R. § 312.21(c) for the United States, as amended from time to time, or the corresponding regulations for a comparable filing with a comparable regulatory authority in a country other than the United States. 

1.33    “Proof of Concept” shall have the meaning set forth in the Stock Purchase Agreement. 

1.34    “Proprietary Materials” means any tangible chemical, biological or physical materials furnished
by or on behalf of one Party to the other Party in connection with this Agreement, whether or not specifically designated as proprietary by the Transferring Party. 

1.35    “Regulatory Approval” means all approvals necessary for the manufacture, marketing, importation
and sale of a Licensed Product for one or more indications in the Field and in a country or regulatory jurisdiction, which may include, without limitation, satisfaction of all applicable regulatory and notification requirements, [***]. 

1.36    “Regulatory Authority” means, in a particular country or regulatory jurisdiction, any applicable
Governmental Authority involved in granting Regulatory Approval and/or, to the extent required in such country or regulatory jurisdiction, pricing or reimbursement approval of a Licensed Product in such country or regulatory jurisdiction. 

1.37    “Reporting Period” shall begin on the first day of each calendar quarter (i.e., January 1,
April 1, July 1, and October 1) and end on the last day of such calendar quarter (i.e., March 31, June 30, September 30, and December 31)^ 

1.38    “Royalty Termination Date” shall mean, on a
country-by-country and Licensed Product-by Licensed Product basis, the date of the expiration or termination of the last to expire of a Valid Claim within the Licensed
Patents that covers such Licensed Product in such country or, if there is no Valid Claim within the Licensed Patents that covers the use, composition or sale of such Licensed Product in such country, the date that is ten (10) years after
the First Commercial Sale of such Licensed Product in such country. 
 1.39    “Sublicensee” shall mean
any person or entity to which a sublicense has been granted by Company under the Licensed Technology, or with respect to the Licensed Products, pursuant to this Agreement. 

1.40    “Term” shall mean the term of this Agreement, which shall commence on the Effective Date and
shall remain in effect until the first to occur of: (a) the date that is the thirtieth (30th) anniversary of the Effective Date; or (b) a date when the Agreement is earlier terminated
pursuant to Article 15. 
 1.41    “Territory” shall mean worldwide. 

1.42    “Third Party” means any person other than Company or MDACC or an Affiliate of either of them.

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 5 

 1.43    “Valid Claim” shall mean either: (i) a
claim of any issued, unexpired patent that has not been revoked or held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and that has
not been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (ii) [***]. 
 ARTICLE 2 

GRANT OF RIGHTS 

2.1    License Grants to Company. 

(a)    Subject to the terms and conditions of this Agreement, Board hereby grants to Company for the Term an exclusive
license, with the right to sublicense through multiple tiers, under the Licensed Technology, to research, have researched, develop, have developed, make, have made, use, have used, sell, have sold, offer to sell, have offered for sale, import, have
imported, export and have exported Licensed Products in the Field in the Territory. 
 (b)    MDACC and Board
acknowledge and agree that, during the Term, subject only to a license granted to the United States Government pursuant to federal law, neither shall directly or indirectly grant any licenses or other rights inconsistent with this
Section 2.1. 
 2.2    Sublicenses. 

(a)    Company shall have the right to grant sublicenses of the rights and licenses granted to Company hereunder through
multiple tiers, provided that each such sublicense is in writing. 
 (b)    Company shall incorporate terms and
conditions into its sublicense agreements sufficient to enable Company to comply with this Agreement. 
 (c)    All
sublicense agreements will terminate upon termination of this Agreement for any reason; provided, however, if Company has sublicensed to a Sublicensee all license rights granted to Company under Section 2.1, then such sublicense agreement shall
survive termination of this Agreement if the Sublicensee: (i) is not an Affiliate of Company; (ii) is not in material breach of the sublicense agreement; (in) agrees to assume all financial obligations of Company owed to
Board and/or MDACC under the Stock Purchase Agreement and this Agreement; (iv) agrees to assume the non-financial obligations of Company under this Agreement, and (v) agrees to pay MDACC all consideration owed or that would
have been owed to Company under the sublicense agreement. 
 2.3    License Grant to MDACC. Subject to the terms
and conditions of this Agreement, Company hereby grants to MDACC for the Term a non-exclusive license under the Company Technology solely to the extent necessary for MDACC to carry out its obligations under the Development Plan. 

2.4    Rights from BridgeBio Pharma LLC. Company shall obtain from BridgeBio Pharma LLC
(“BridgeBio”) at no cost to Company, a license to (with the right to sublicense to MDACC) or assignment of any rights arising under the laws of patent, copyright, or other intellectual property, to the extent that BridgeBio has the
right to license or assign the foregoing and to the extent reasonably necessary for the research, development, manufacture, or commercialization of a Licensed Product in the Field. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 6 

 2.5    Retained Rights. 

(a)    Board and MDACC shall retain the right to use the Licensed Patents in performing non-commercial, non-clinical, basic research or for educational purposes (but in no case when such research is sponsored by any for-profit entity). 

(b)    Board and/or MDACC shall retain the right to grant non-exclusive licenses
to other nonprofit or academic institutions to use the Licensed Patents for use in performing non-commercial, non-clinical, basic research or for educational purposes
(but in no case when sponsored by any for-profit entity). 
 (c)    Board and/or
MDACC shall retain the right to publish the general scientific findings from research related to Licensed Technology, subject to the terms of Article 13-Confidential Information. 

2.6    No Additional Rights. Nothing in this Agreement shall be construed to confer any rights upon Company by
implication, estoppel, or otherwise as to any rights of Board or MDACC other than the Licensed Technology. 
 ARTICLE 3 

GOVERNANCE 

3.1    Joint Steering Committee. 

(a)    Formation; Composition. Within thirty (30) days of the Effective Date, the Parties will establish a
joint steering committee (the “Joint Steering Committee” or “JSC”) comprised of three (3) representatives from MDACC and three (3) representatives from Company with sufficient seniority within the
applicable Party to make decisions arising within the scope of the JSC’s responsibilities. The JSC may change its size from time to time by mutual consent of its members, provided that the JSC will consist at all times of an equal number of
representatives of each of MDACC and Company. Each Party may replace its JSC representatives at any time upon written notice to the other Party. 

(b)    Specific Responsibilities. The JSC will: 

(i)    oversee the Development Plan; 

(ii)    approve any amendments to the Development Plan (including any changes to the budget that are
greater than [***] of the then-current budget for the then-current Calendar Year); 
 (iii)    resolve
any disagreement between the Parties relating to the Development Plan: 
 (iv)    establish such
additional subcommittees as it deems necessary to achieve the objectives and intent of the Development Plan; 

(v)    resolve issues presented to it by, and disputes within the JDC; and 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 7 

 (vi)    perform such other functions as appropriate, and
direct the JDC to perform such other functions as appropriate, to further the purposes of this Agreement, in each case as agreed in writing by MDACC and Company. 

(c)    Meetings. During the Term, the JSC will meet at least [***] unless agreed upon otherwise by the Parties. The
JSC may meet in person, by videoconference or by teleconference. Each of MDACC and Company will bear the expense of its respective JSC members’ participation in JSC meetings. Meetings of the JSC will be effective only if at least one
(1) representative of each such Party is present or participating in such meeting. 
 (d)    Decision
Making. The representatives from each Party on the JSC will have, collectively, one (1) vote on behalf of that Party, and all decision making will be by consensus. If the JSC is unable to reach consensus on any issue or matter for which it
is responsible, it will be escalated to Company’s chief executive officer for decision. 
 3.2    Joint
Development Committee. 
 (a)    Formulation: Composition. Within [***] days of the Effective Date, the
Parties will establish a development committee (the “Development Committee” or “JDC”) comprised of an equal number of representatives from MDACC and Company. The JDC may change its size from time to time by mutual
consent of its members, provided that the JDC will consist at all times of an equal number of representatives of each of MDACC and Company. Each Party may replace its JDC representatives at any time upon written notice to the other Party. 

(b)    Specific Responsibilities. The JDC will: 

(i)    oversee, manage, coordinate and integrate the activities of the Parties under the Development Plan;

 (ii)    make key decisions during the progress of the Development Plan; and 

(iii)    perform such other functions as appropriate to further the purposes of this Agreement, as directed
by the JSC in accordance with Article 4. 
 (c)    Meetings. The JDC will meet at least [***], unless MDACC and
Company mutually agree in writing to a different frequency. The JDC may meet in person, by videoconference, or by teleconference. Meetings of the JDC will be effective only if all representatives of each Party are present or participating in such
meeting. Each Party will bear the expense of its respective JDC members’ participation in JDC meetings. 
 ARTICLE 4 

DEVELOPMENT 

4.1    Overview. MDACC and Company desire and intend to collaborate with respect to the research and Development of
Licensed Products in the Field in the Territory under the direction of the JDC and JSC. Such Parties’ respective responsibilities for the research and Development of the Licensed Products are set forth in this Article 4 and in the Development
Plan. In general, Company shall be primarily responsible for the Development and Regulatory Approval of the Licensed Products in the Territory, and MDACC shall assist Company with Development activities with respect to clinical candidate
identification, translational research and management and coordination of IND-enabling activities or as the Parties may otherwise agree in writing, in each case as set forth in the Development Plan and subject to reimbursement under this Agreement.

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 8 

 4.2    Development Plan. 

(a)    General. The development activities of MDACC and Company with respect to the Licensed Products shall be
governed by a development plan agreed upon by such Parties, which will include a summary of all clinical studies to be performed for the Licensed Products in the Territory and will include budgets and timelines regarding such activities (the
“Development Plan”). The Development Plan shall also specific the plans and timeline for preparing the necessary regulatory filings and for obtaining Regulatory Approval for the Licensed Products in the Territory. The initial
Development Plan agreed to by MDACC and Company is attached to this Agreement as Exhibit B. Each of MDACC and Company shall conduct its Development activities in accordance with the then-current Development Plan. 

(b)    Updates to Development Plan. From time to time during the term of this Agreement, the JDC shall update and
amend, as appropriate, the then-current Development Plan, including to identify specific Development activities to be performed by MDACC and Company, and shall submit such amended Development Plan to the JSC for approval. Once approved by the JSC,
each updated or amended Development Plan shall become effective and supersede the previous Development Plan as of the date of such approval. Notwithstanding the provisions in Section 3.1(d), Company shall not exercise its final decision making
authority on the JSC to amend the Development Plan to modify the Development activities assigned to MDACC thereunder without the consent of MDACC. Each update to the Development Plan shall reflect that time is of the essence for the Development of
Licensed products. 
 4.3    MDACC Development Activities. 

(a)    MDACC shall use Commercially Reasonable Efforts to conduct the Development activities assigned to it in the
Development Plan (the “MDACC Development Activities”). MDACC shall conduct all MDACC Development Activities in accordance with the Development Plan and under the direction of the JDC and JSC. 

(b)    For as long as MDACC is conducting MDACC Development Activities, the status, progress and results of MDACC
Development activities shall be discussed in reasonable detail at meetings of the JDC, and MDACC shall provide the JDC with a written report on the status and progress of such MDACC Development Activities on a [***] basis. In addition, MDACC shall
make available to Company such information about MDACC Development Activities as may be reasonably requested by Company from time to time. 

4.4    Company Development Activities. 

(a)    Company shall use Commercially Reasonable Efforts to conduct all Development activities assigned to Company under
the Development Plan (the “Company Development Activities”), in accordance with the Development Plan and the direction of the JDC and JSC. Company shall conduct all Company Development Activities in accordance with the Development
Plan and under the direction of the JDC and JSC. 
 (b)    The status, progress and results of Company’s
Development Activities shall be discussed in reasonable detail at meetings of the JDC, and Company shall provide the JDC with a written report on the status and progress of such Company Development Activities on a [***] basis. In addition, Company
shall make available to MDACC such information about Company Development Activities as may be reasonably requested by MDACC from time to time. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 9 

 4.5    Development Costs. 

(a)    Company shall bear: (i) all Development costs and expenses incurred by or on behalf of Company in accordance
with the Development Plan; (ii) all Development costs incurred by or on behalf of MDACC after the Effective Date in performance of the MDACC Development Activities in accordance with the Development Plan; and (iii) any and
all other costs incurred by Company in connection with the research, Manufacture and development of the Licensed Products. 

(b)    On a [***] basis, MDACC shall provide an invoice to Company setting forth the total FTE Costs (including the amount
of time actually spent by MDACC’s FTEs on Development activities, and a brief description of the work performed by such FTEs) incurred by MDACC in the performance of MDACC Development Activities until the date of such invoice, and Company
shall, within [***] days after receiving such invoice, reimburse MDACC for the full amount of such FTE Costs incurred by MDACC; provided that, Company shall not be responsible for the payment of any costs and expenses (including FTE Costs) that are
incurred by MDACC for any Development activity that are not set forth in the then-current Development Plan, and such costs and expenses will be borne entirely by MDACC unless otherwise approved by Company in writing. 

4.6    Compliance. 

(a)    Each of MDACC and Company agrees that in performing its obligations under this Agreement: (i) it shall comply with
all Applicable Laws; and (ii) it will not employ or engage any person who has been debarred by any Regulatory Authority, or, to such Party’s knowledge, is the subject of debarment proceedings by a Regulatory Authority. 

(b)    Each of MDACC and Company shall maintain complete, current and accurate records of all work conducted by it under
the Development Plan, and all data and other Information resulting from such work. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner
appropriate for regulatory purposes. Each such Party shall document all preclinical studies and clinical trials in formal written study reports according to applicable national and international (e.g., ICH, GCP, GLP, and GMP) guidelines. Each such
Party shall have the right to review such records maintained by the other Party at reasonable times, upon written request, which shall not exceed once a year. 

4.7    Third Party Contractors. Each of MDACC and Company will have the right to engage Third Party contractors to
perform its respective Development activities, subject to the execution by each such Third Party contractor of an agreement containing provisions with respect to confidentiality and assignment of Collaboration Technology that are consistent with,
and comparable in scope to, Articles 9 and 13 of this Agreement. Each such Party remains primarily responsible for the performance of such Third Party contractor(s). 

4.8    Use of Proprietary Materials. From time to time during the Term, either of MDACC or Company (the
“Transferring Party”) may supply the other Party (the “Receiving Party”) with Proprietary Materials of the Transferring Party for use in the Research Project or any Development Program. In connection therewith, each
Receiving Party hereby agrees that: (a) upon the reasonable written request of the Transferring Party, the Receiving Party will document the material transfer in writing prior to transfer of any such Proprietary Materials; (b) even in the absence of
written documentation of such material transfer, the Receiving Party will not use the Proprietary Materials for any purpose other than exercising its rights or performing its obligations hereunder; (c) it will use such Proprietary Materials only in
compliance with all Applicable Laws; (d) it will not transfer any such Proprietary Materials to any Third Party without the prior written consent of the Transferring Party, except for the transfer of Development

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 10 

 
Candidates and Licensed Products for use in Clinical Trials; (e) it will not acquire any rights of ownership, or title in or to such Proprietary Materials as a result of such supply by the
Transferring Party; and (f) upon the expiration or termination of this Agreement, if requested by the Transferring Party, it will destroy or return any such Proprietary Materials that are not the subject of the grant of a continuing
license hereunder. 
 ARTICLE 5 

COMMERCIALIZATION 

5.1    Commercialization Responsibility. As between the Parties, Company will be solely responsible for the
Commercialization of the Licensed Products in the Field in the Territory, in compliance with all Applicable Laws. 

5.2    Diligence. Company shall use Commercially Reasonable Efforts to Commercialize the Licensed Product following
Regulatory Approval of the Licensed Products in the Territory in accordance with this Agreement. Notwithstanding anything to the contrary herein, Company or its Affiliates will not be obligated to undertake or continue any Commercialization
activities with respect to any Licensed Product if Company (or any of its Affiliates) reasonably determines that performance of such Commercialization activity would violate Applicable Law or infringe or misappropriate a Third Party’s
intellectual property. 
 5.3    Trademarks. Subject to Section 14.3, Company shall have the right to select
the trademark to be used in connection with the commercialization of the Licensed Products in the Territory (the “Product Trademark”), and, as between the Parties, shall have all rights in and to such Product Trademark in the
Territory, provided that the Product Trademark is not already owned by the Board at the time of Company’s selection of the trademark. Provided that the Product Trademark is not already owned by the Board at the time of Company’s selection
of the trademark, Company will be responsible for the filing, prosecution, maintenance and defense of all registrations of the Product Trademark, and will be responsible for the payment of any costs relating to filing, prosecution, maintenance and
defense of all Product Trademarks in the Territory. 
 5.4    Commercialization Reports. Company will inform
MDACC concerning the progress of its efforts to Commercialize the Licensed Products, through annual updates that will: (a) summarize Company’s efforts to Commercialize such Licensed Products; and (b) identify any regulatory
filings or Regulatory Approval applications with respect to the Licensed Products that Company has filed, sought or obtained in the prior [***] month period. 

ARTICLE 6 
 MANUFACTURING

 6.1    Generally. As between the Parties, Company shall be solely responsible for manufacture of Licensed
Product for supply in the Territory, for both clinical and commercial purposes. Company will identify and engage with Third Party contract manufacturers to handle manufacturing of the Licensed Products. Company will consult with MDACC on the
selection of any Third Party contract manufacturers and will consider in good faith any MDACC input on such Third Party contract manufacturers. 

6.2    Manufacturing Costs. [***] shall be solely responsible for all fees and costs for the manufacture of
Licensed Products in the Field in the Territory. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 11 

 ARTICLE 7 

FINANCIAL TERMS 

7.1    Consideration for Grant of Rights. In addition to the issuance of the Shares (as defined in the Stock
Purchase Agreement) to Board and the other obligations of Company pursuant to the Stock Purchase Agreement, as further consideration for Board’s grant of rights in the Licensed Technology, Company hereby agrees as follows: 

(a)    Milestone. [***]. 

(b)    Running Royalties. Company shall pay to MDACC royalties on Net Sales of Licensed Products sold by Company,
its Affiliates and Sublicensees as follows: 
 (i)    If [***], MDACC shall receive a [***] Percent
([***]%) royalty on Net Sales; 
 (ii)    If a [***], MDACC shall receive, in addition to any other
royalties or amounts paid hereunder to MDACC, an amount equal to [***] Percent ([***]%) royalty on Net Sales; 

(iii)    If [***], MDACC shall receive, in addition to any other royalties or amounts paid hereunder to
MDACC, an amount equal to [***] Percent ([***]%) royalty on Net Sales; and 
 (iv)    If [***], MDACC
shall receive, in addition to any other royalties or amounts paid hereunder to MDACC, an amount equal to [***] Percent ([***]%) royalty on Net Sales. 

Running royalties shall be payable for each Reporting Period and shall be due to MDACC within [***] days of the end of each Reporting Period. Notwithstanding
the provisions of this Section 7.1(b), in countries in the Territory where the use, composition or sale of a Licensed Product would not infringe a Valid Claim of Licensed Patents, then the royalties as they become due under this
Section 7.1(b) on Net Sales of such Licensed Product in such countries shall be reduced by [***]. 

(c)    Royalty Stacking. To the extent that Company or any of its Affiliates or Sublicensees obtains licenses to
Third Party patent rights or other intellectual property in order to practice the Licensed Patents or to Develop or Commercialize any Licensed Products, Company may deduct up to [***] of the royalties payable and actually paid to such Third
Party(ies) for such patents rights or other intellectual property from any royalty due to MDACC under Section 7.1(b) up to an amount equal to [***] of the running royalties owed in any Reporting Period hereunder, with any excess Third Party
royalties carried over into next succeeding Reporting Periods until exhausted. 
 (d)    Royalty Floor. In no
event shall the royalty payable by Company pursuant to Section 7.1(b) be reduced by application of Section 7.1(c) to less than [***] Percent ([***]%) royalty on Net Sales. 

(e)    No Multiple Royalties. If the manufacture, use or sale of any Licensed Product is covered by more than one
of the Licensed Patents, multiple royalties shall not be due. 
 (f)    Duration of Royalty Obligations. The
royalty obligations of Company shall be on a country-by-country and Licensed
Product-by-Licensed Product basis, and shall begin on the First 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 12 

 
Commercial Sale of such Licensed Product in a country and continue (i), with respect to the royalties pursuant to Sections 7. l(b)(i)and 7. l(b)(ii), for three (3) years thereafter, and
(ii) with respect to the royalties pursuant to Sections 7.1(b)(iii) and 7.1(b)(iv), until the Royalty Termination Date for such Licensed Product in such country. Upon the Royalty Termination Date with respect to a Licensed Product in a
country and full payment of all amounts due and payable to MDACC, the license grants contained in Sections 2.1 shall become fully paid-up and royalty-free for such Licensed Product in such country. 

(g)    Combination Products. In the event that all components of a Combination Product were not sold or
provided separately during the same or immediately preceding Reporting Period as described in the definition of “Net Sales” in Section 1.25, then until the Parties agree upon a proration factor as described in
Section 1.25, Company shall place in escrow an amount equal to the payment that MDACC would be due if the no proration factor is applied such that the entire product sold or otherwise transferred to a final customer was a Licensed
Product. 
 (h)    Method of Payment. All amounts payable hereunder by Company will be paid in United States
funds without deductions for taxes, assessments, fees, or charges of any kind. Checks are to be made payable to The University of Texas M.D. Anderson Cancer Center, and sent by United States mail to Box 4390, Houston, Texas 77210-4390, or by
wire transfer to: 
 [***] 

REFERENCE: include title and Effective Date of Agreement and type of payment (e.g., royalty, patent expense reimbursement (identify patent
number), etc. 
 (i)    Payments in U.S. Dollars. All payments due under this Agreement shall be payable in
United States dollars. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the United States (as reported in the Wall Street Journal) on the last working day of the calendar quarter of the applicable
Reporting Period. 
 ARTICLE 8 

REPORTS AND RECORDS 

8.1    Frequency of Reports. 

(a)    Before First Commercial Sale. Prior to the First Commercial Sale of any Licensed Product, Company shall
deliver reports to MDACC annually, within [***] days after the end of each calendar year, containing information concerning the immediately preceding calendar year, as further described in Section 8.2. 

(b)    Upon First Commercial Sale of a Licensed Product. Company shall report to MDACC the date of First Commercial
Sale of a Licensed Product within [***] days of occurrence in each country. 
 (c)    After First Commercial Sale.
After the First Commercial Sale of a Licensed Product in a country, Company shall deliver reports to MDACC within [***] days of the end of each Reporting Period through the Royalty Termination Date for such Licensed Product in such country,
containing information concerning the immediately preceding Reporting Period, as further described in Section 8.2. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 13 

 8.2    Content of Reports and Payments. Each report delivered by
Company to MDACC shall contain at least the following information for the immediately preceding Reporting Period: 

(a)    the number of Licensed Products sold by Company, its Affiliates and Sublicensees to independent third parties in
each country; 
 (b)    Company the gross price charged by Company, its Affiliates and Sublicensees for each Licensed
Product Company in each country; 
 (c)    calculation of Net Sales for the applicable Reporting Period in each country,
including, without limitation, a listing of applicable deductions; and 
 (d)    total royalty payable on Net Sales in
U.S. dollars, together with the exchange rates used for conversion. , 
 If no amounts are due to MDACC for any Reporting Period, the report shall so state.

 8.3    Records. Company shall maintain, and shall cause its Affiliates and Sublicensees to maintain, complete
and accurate records relating to amounts payable to MDACC in relation to this Agreement. The relevant entity shall retain such records for at least [***] following the end of the calendar year to which they pertain, during which time a certified,
independent public accountant selected by MDACC and reasonably acceptable to Company shall have the right, [***], to inspect such records during normal business hours to verify any reports and payments made or compliance in other respects under this
Agreement. In the event that any audit performed under this Section 8.3 reveals [***] shall bear the full out-of-pocket cost of such audit. Company shall promptly remit any past due amounts to MDACC within [***] days of receiving notice thereof from
MDACC, regardless of whether such notice is the result of an audit. 
 8.4    Confidentiality. The reports and
records provided by Company hereunder shall be regarded as Company’s Confidential Information and subject to the terms and conditions of Article 13. 

ARTICLE 9 
 INTELLECTUAL
PROPERTY 
 9.1    Ownership of Inventions. Ownership of innovations, inventions or discoveries (whether or
not patentable or copyrightable) that are invented or discovered under this Agreement shall be determined by inventorship in accordance with United States law. Notwithstanding the foregoing, Collaboration Technology shall be solely owned by Company.
MDACC must promptly disclose to Company all Collaboration Technology, and Board and MDACC hereby assign all Collaboration Technology to Company. At Company’s request [***], MDACC shall execute, or cause to have executed, such documents and take
such other actions and Company reasonably deems necessary or appropriate to assist Company in obtaining, recording or enforcing patents, copyrights, or assignments thereof in Company’s name covering any Collaboration Technology hereunder. 

9.2    Responsibility for Licensed Patents. MDACC will, to the extent approved by System, appoint Company as its
agent to prepare, file, prosecute, maintain and defend in all agency proceedings (e.g., reissues, reexaminations, oppositions and interferences) all of the Licensed Patents during the Term. Company shall copy MDACC on all patent prosecution
documents and give MDACC reasonable opportunities to advise Company on such filing, prosecution and maintenance. In the event Company desires to abandon any patent or patent application within the Licensed Patents, Company shall provide MDACC with
reasonable prior written notice of such intended abandonment or decline of responsibility. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 14 

 If MDACC elects to continue such patent or patent application, the Parties shall consult and Company may
elect to retain responsibility therefor. Otherwise, the right to prepare, file, prosecute, maintain and defend the relevant Licensed Patents shall revert to MDACC and the costs arising from exercising such right shall be at [***]. In such event,
such [***] paid-for rights shall be removed from the definition of Licensed Patents under this Agreement and the licenses granted to Company and its Affiliates as to such rights shall terminate. 

9.3    Responsibility for Collaboration Technology. Company shall be solely responsible to file, prosecute and
maintain Patent Rights covering any Collaboration Technology (collectively, “Collaboration Patents”), in its sole discretion [***]. 

9.4    Payment of Expenses. Payment of all fees and costs, including, without limitation, attorneys’ fees, for
the filing, prosecution and maintenance of the Licensed Patents incurred by [***] before the Effective Date shall be the responsibility of [***]. As of the Effective Date, [***] has incurred approximately [***] for such patent-related fees and
costs. [***] shall reimburse [***] for such expenses within [***] days after receipt of an invoice for expenses from [***]. 

9.5    Patent Extensions and Orange Book Listings. If elections with respect to obtaining patent term extensions
(including, without limitation, any available pediatric extensions) or supplemental protection certificates or their equivalents in any country with respect to Licensed Patents are available, Company shall have the sole and exclusive right to make
any such elections based on Licensed Products. With respect to data exclusivity periods (such as those periods listed in the FDA’s Orange Book (including, without limitation, any available pediatric extensions) or periods under national
implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or orphan exclusivity periods, and all equivalents in any country), Company shall have the sole and exclusive right to seek and maintain all such data exclusivity periods available for
the Licensed Products. With respect to all of the rights and activities identified in this Section 9.5, MDACC will, to the extent approved by System, appoint Company as its agent for such purposes with the authority to act on
MDACC’s behalf with respect to the Licensed Patents in a manner consistent with this Agreement. 
 ARTICLE 10 

INFRINGEMENT 

10.1    Notification of Infringement. Each of MDACC and Company agrees to provide written notice to the other
promptly after becoming aware of any existing or threatened infringement of the Licensed Patents or Collaboration Patents by a Third Party and of any available evidence thereof, including any “patent certification” filed in the United
States under 21 U.S.C. §355(b)(2) or 21 U.S.C. §355(j)(2) or similar provisions in other jurisdictions and of any declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability or non-infringement of any of the Licensed Patents or Collaboration Patents. 

10.2    Right to Prosecute Infringements. 

(a)    Company Right to Prosecute. Company shall have the first and exclusive right, but not the obligation, under
its own control [***], to prosecute any Third Party infringement of the Licensed Patents and Collaboration Patents, subject to Section 10.3. The total cost of any such infringement action commenced or defended solely by Company
shall be borne by [***]. 
 (b)    MDACC Right to Prosecute. If within [***] after having been notified of any
alleged infringement that is material and competitive in the marketplace Company is unsuccessful in persuading the alleged infringer to desist and shall not have brought and shall not be diligently prosecuting an infringement action, then MDACC
shall have the right, but shall not be obligated, under its own control [***], to prosecute any infringement of the Licensed Patents. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 15 

 10.3    Recovery. In the event that either Party exercises the
rights conferred in this Article 10 with respect to the Licensed Patents and recovers any damages or other sums in such action, such damages or other sums recovered shall first be applied to all out-of-pocket costs and expenses incurred by the
Parties in connection therewith (including, without limitation, attorneys’ fees). If such recovery is insufficient to cover all such costs and expenses of both Parties, then the recovery shall be proportionately allocated between the Parties in
accordance with the amounts of documented out-of-pocket costs and expenses that were incurred by each Party in connection with prosecuting any infringement of the Licensed Patents. If after such reimbursement of out-of-pocket costs and expenses any
funds remain from such damages or other sums recovered, MDACC shall receive a percentage of the recovery that corresponds to MD Anderson’s equity ownership of Company (or if Company has been merged into another entity, the percentage of the
recovery that corresponds to MD Anderson’s equity ownership of Company at the time of such merger). Notwithstanding the foregoing, in the event that Company does not file suit but MDACC chooses to file suit, then the recovery that remains after
reimbursement of out-of-pocket costs and expenses shall be allocated as follows: MDACC shall receive [***] and Company shall receive [***] of the remaining recovery. 

10.4    Cooperation. In any suit or dispute involving an infringer, at the request and expense of the party
bringing suit, the other party will permit access during regular business hours, to all relevant personnel, records, papers, information, samples, specimens, and the like in its possession. 

10.5    Patent Certifications. MDACC shall notify and provide Company with copies of any allegations of alleged
patent invalidity, unenforceability or non-infringement of a Patent Right pursuant to a Paragraph IV Patent Certification by a Third Party filing an Abbreviated New Drug Application, an application under §505(b)(2) or any other similar patent
certification by a Third Party, and any foreign equivalent thereof. Such notification and copies shall be provided to Company within [***] business days after MDACC receives such certification. 

10.6    Claims by Third Parties. If legal action is threatened or brought against either of Company or MDACC (or
any Affiliate of either Party) by a Third Party alleging misappropriation of Information or infringement of Patent Rights, by reason of activities involving the Licensed Product, such Party will notify the other Party within [***] days of the
earlier of receipt of service of process in such action, suit or proceeding, or the date such Party becomes aware that such action, suit or proceeding has been instituted, or in the case of MDACC, the date MDACC’s Office of Technology
Commercialization becomes aware that such action, suit or proceeding has been instituted. Promptly after such notification, MDACC and Company will confer to consider the Third Party claim, and an appropriate course of action. Each Party will have
the right to defend itself against a law suit that names it as a defendant. Neither MDACC nor Company will enter into any settlement of any claim described in this Section 10.6 that affects the other Party’s rights or interests, without
such other Party’s written consent, which will not be unreasonably withheld or delayed. 
 ARTICLE 11 

INDEMNIFICATION AND INSURANCE 

11.1    Indemnification by Company. Company will indemnify, subject to the statutory duties of the Texas State
Attorney General defend, and hold harmless MDACC, System, and their respective Regents, directors, officers, employees and agents, and their respective successors, heirs and assigns (collectively, the “MDACC Indemnitees”), against
all liabilities, damages, losses and expenses (including reasonable attorneys’ fees and expenses of litigation) (collectively, “Losses”) incurred by or imposed 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 16 

 
upon any of the MDACC Indemnitees, as a direct result of claims, suits, actions, demands or judgments of Third Parties, arising out of: (a) the conduct of Company Development Activities by
Company or any of its Affiliates; (b) the manufacture and Commercialization of any Licensed Product by Company or any of its Affiliates; (c) any breach of this Agreement by Company or any of its Affiliates; but only to the
extent that any such Loss is the result of gross negligence or willful misconduct of Company or its Affiliates, excluding any Losses that result from the breach of this Agreement by MDACC, or for which MDACC has an obligation to indemnify Company
Indemnitees pursuant to Section 11.2. 
 11.2    Indemnification by MDACC. To the extent authorized
by the constitution and laws of the State of Texas, MDACC will indemnify, defend and hold harmless Company, its subsidiaries, their respective directors, officers, employees and agents, and their respective successors, heirs and assigns
(collectively, the “Company Indemnitees”), against all Losses incurred by or imposed upon any of the Company Indemnitees, as a direct result of claims, suits, actions, demands or judgments of Third Parties, arising out of:
(a) the conduct of MDACC Development Activities by MDACC or any of its Affiliates; (b) any breach of this Agreement by MDACC or any of its Affiliates; but only to the extent that any such Loss is the result of gross negligence or willful
misconduct of MDACC or its Affiliates, excluding any Losses that result from the breach of this Agreement by Company, or for which Company has an obligation to indemnify MDACC Indemnitees pursuant to Section 11.1 

11.3    Insurance. Each Party will procure and maintain insurance, or self-insure at its own expense, in a manner
adequate to cover its obligations under this Agreement and consistent with normal business practices of prudent companies similarly situated, at all times during the Term and for a period of [***] years thereafter. It is understood that such
insurance will not be construed to create a limit of either Party’s liability with respect to its indemnification obligations under this Article 11. 

ARTICLE 12 

REPRESENTATIONS OR WARRANTIES 

12.1    Mutual Representations and Certifications. MDACC and Company each represents and certifies to the other, as
follows: 
 (a)    Organization. It is a corporation or other legal entity duly organized, validly existing and
in good standing under the laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement. 

(b)    Authorization. The execution and delivery of this Agreement and the performance by it of the transactions
contemplated hereby have been duly authorized by all necessary legally required action and will not violate: (i) such Party’s certificate of incorporation or bylaws, or other terms and conditions of such Party’s existence;
(ii) any agreement, instrument or contractual obligation to which such Party is bound in any material respect; or (iii) any order, writ, judgment, injunction, decree, determination or award of any court or governmental agency
presently in effect applicable to such Party. 
 (c)    Binding Agreement. This Agreement is a legal, valid and
binding obligation of such Party, enforceable against it in accordance with its terms and conditions. 
 (d)    No
Inconsistent Obligation. It is not under any obligation, contractual or otherwise, to any Person that conflicts with or is inconsistent in any respect with the terms of this Agreement. 

12.2    Additional Representations and Warranties of MDACC. MDACC represents and warrants that: (a) it and/or Board
solely and exclusively owns the patents and applications included within 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 17 

 
the Licensed Patents(b) it and/or Board solely and exclusively owns the inventions and discoveries set forth in the MDACC Invention Disclosure Report listed on Exhibit A and the Information
included within the Licensed Know-How; (c) it and/or Board has the power and authority to grant the licenses provided for herein to Company, and to the knowledge of MDACC, neither MDACC nor Board has earlier granted, or assumed any obligation
to grant, any rights in the Licensed Patents or Licensed Know-How to any Third Party that would conflict with the rights granted to Company herein, subject to Section 17.11; and (d) to MDACC’s knowledge, there is no
infringement of the Licensed Patents or misappropriation of the Licensed Know-How by any Third Party. 

12.3    Additional Representations and Warranties of COMPANY. Company represents and warrants that: (a) it
solely and exclusively owns the patents and applications included within Company Patents; (b) it solely and exclusively owns all of the Information included within Company Know-How, (c) it has the power and authority to grant
the licenses provided for herein to MDACC, and that it has not earlier granted, or assumed any obligation to grant, any rights in the Company Patents or Company Know-How to any Third Party that would conflict with the rights granted to MDACC herein;
and (d) to Company’s knowledge, there is no infringement of the Company Patents or misappropriation of the Company Know-How by any Third Party. 

12.4    Disclaimer of Warranties. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY
WARRANTY WITH RESPECT TO ANY KNOW-HOW, PATENT SCOPE, VALIDITY, OR ENFORCEABILITY, REGULATORY APPROVAL, COST OF DEVELOPMENT, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING WARRANTIES OF MERCHANTABILITY, OPERABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. 

12.5    Limitation of Liability. TO THE EXTENT PERMITTED BY APPLICABLE LAWS, NEITHER PARTY WILL BE LIABLE TO THE
OTHER PARTY OR ANY OF ITS AFFILIATES FOR ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING LOST PROFITS OR LOST REVENUES, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING,
NOTHING IN THIS SECTION 12.5 IS INTENDED TO OR WILL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY HEREUNDER. 

ARTICLE 13 
 CONFIDENTIAL
INFORMATION 
 13.1    Confidentiality. 

(a)    Obligations. MDACC and Company each recognizes that the other Party’s Confidential Information and
Proprietary Materials constitute highly valuable assets of such other Party. MDACC and Company each agrees that, subject to Section 13.1(b), during the Term and for an additional [***] years after termination or expiration of this
Agreement: (i) it will not disclose, and will cause its Affiliates not to disclose, any Confidential Information or Proprietary Materials of the other Party; and (ii) it will not use, and will cause its Affiliates not to use,
any Confidential Information or Proprietary Materials of the other Party, except as expressly permitted in this Agreement. 

(b)    Limited Disclosure. MDACC and Company each agree that disclosure of its Confidential Information or any
transfer of its Proprietary Materials may be made by the other Party to any of its Affiliates, employees, consultants, contractors, subcontractors, agents or other Third Parties to enable such other Party to exercise its rights or to carry out its
responsibilities under this Agreement; 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 18 

 
provided, that any such disclosure or transfer will be made only to Persons who are bound by obligations no less stringent than those described in the provisions herein. In addition, MDACC and
Company each agrees that the other Party may disclose its Confidential Information: (i) on a need-to-know basis to such other Party’s professional, legal and financial advisors; (ii) as reasonably necessary in connection with
an actual or potential (A) permitted license or sublicense of such other Party’s rights hereunder, (B) debt or equity financing of such other Party, or (C) merger, acquisition, consolidation, share exchange
or other similar transaction involving such Party and any Third Party; (iii) to any Third Party that is or may be engaged by a Party to perform services in connection with the research, Development or the Commercialization of Licensed
Products as necessary to enable such Third Party to perform such services; and (iv) for any other purpose with the other Party’s written consent, which consent will not be unreasonably withheld, conditioned or delayed; provided,
that, any such disclosure or transfer in (i) - (iv) will only be made to persons who are bound by written obligations no less restrictive than those described in Section 13.1 (c). Each of MDACC and Company further agrees that the other
Party may disclose such Party’s Confidential Information or provide such Party’s Proprietary Materials: (v) as reasonably necessary to file, prosecute or maintain Patent Rights, or to file, prosecute or defend litigation related to
Patent Rights, in accordance with this Agreement, provided, that in the case of any disclosure under this clause (v), to the extent reasonably possible, the disclosing Party will provide the other Party with reasonable advance notice of and an
opportunity to comment on any such required disclosure; or (vi) as required by Applicable Laws; provided, that in the case of any disclosure under this clause (vi), the disclosing Party will (A) if practicable, provide the other
Party with reasonable advance notice of and an opportunity to comment on any such required disclosure, and (B) if requested by the other Party, cooperate in all reasonable respects with the other Party’s efforts to obtain
confidential treatment or a protective order with respect to any such disclosure, at the other Party’s expense. 

(c)    Employees and Consultants. MDACC and Company each hereby represents that all of its respective employees,
consultants and Third Party contractors, and all of the employees and consultants of its Affiliates, who have access to Confidential Information or Proprietary Materials of the other Party, prior to having such access, are or will be bound by
obligations to maintain such Confidential Information or Proprietary Materials in confidence and not to use such Confidential Information, except as expressly permitted in this Agreement. Each of MDACC and Company agrees to use, and to cause its
Affiliates to use, Commercially Reasonable Efforts to enforce such obligations and to prohibit its employees and consultants from using Confidential Information except as expressly permitted hereunder. In any and all events, each of MDACC and
Company will be liable to the other Party for any disclosure or misuse by such receiving Party’s employees, consultants, Affiliates and Third Party contractors of Confidential Information or Proprietary Materials of the disclosing Party. 

13.2    Publications and Presentations. The JSC will establish rules and procedures for scientific and medical
publications and presentations containing results, data or other information obtained in the collaboration under this Agreement. Such rules and procedures will include requirements for reasonable advance notice and expeditious review of proposed
publications and presentations. Notwithstanding the foregoing: (a) either MDACC or Company, if proposing to make a publication, will deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at
least [***] days prior to submission for publication or presentation; (b) the reviewing Party will have the right to require a delay of up to [***] days in publication or presentation in order to enable preparation and filing of patent
applications protecting intellectual property rights in such information; and (c) each of MDACC and Company will have the right to prohibit disclosure of any of its Confidential Information in any such proposed publication or
presentation. In any permitted publication or presentation by a Party, the other Party’s contribution will be duly recognized, and authorship will be determined in accordance with customary standards. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 19 

 ARTICLE 14 

GENERAL COMPLIANCE WITH LAW 

14.1    Compliance with Laws. Each Party shall use Commercially Reasonable Efforts to comply with all commercially
material Applicable Laws relating to the development, manufacture, use, and sale of Licensed Products. 

14.2    Export Control. Company and its Affiliates and Sublicensees shall comply with all United States laws and
regulations controlling the export of certain commodities and technical data, including, without limitation, all Export Administration Regulations of the United States Department of Commerce. Among other things, these laws and regulations prohibit
or require a license for the export of certain types of commodities and technical data to specified countries. Company hereby gives written assurance that it shall comply with, and shall cause its Affiliates and Sublicensees to comply with, all
United States export control laws and regulations, that it bears sole responsibility for any violation of such laws and regulations by itself or its Affiliates or Sublicensees. 

14.3    Non-Use by Company. Company and its Affiliates and Sublicensees shall not use the name of Board, System,
MDACC, or any variation, adaptation, or abbreviation thereof, or of any of its trustees, officers, faculty, students, employees, or agents, or any trademark owned by Board, System, or MDACC, or any terms of this Agreement in any promotional material
or other public announcement or disclosure without the prior written consent of MDACC. The foregoing notwithstanding, without the consent of MDACC, Company may use the name of (or name of employee of) MDACC, System or Board in routine business
correspondence, or as needed in appropriate regulatory submissions without express written consent. 

14.4    Marking of Licensed Products. To the extent commercially feasible and consistent with prevailing business
practices, Company shall mark, and shall cause its Affiliates and Sublicensees to mark, all Licensed Products that are manufactured or sold under this Agreement with the number of each issued patent under the Licensed Patents that applies to such
Licensed Product. 
 ARTICLE 15 

TERMINATION 

15.1    Voluntary Termination by Company. Company shall have the right to terminate this Agreement, for any reason,
upon at least [***] months prior written notice to MDACC, such notice to state the date at least [***] months in the future upon which termination is to be effective. Notwithstanding anything in this Agreement or the Stock Purchase Agreement to the
contrary, in the event that Company terminates this Agreement pursuant to this Section 15.1, MDACC shall not be required to return or forfeit any payments made to MDACC or equity issued to MDACC under this Agreement or the Stock Purchase
Agreement. 
 15.2    Termination. 

(a)    Nonpayment. In the event Company fails to pay any undisputed amounts due and payable to MDACC under this
Agreement or issue “Funding Shares” to Board that are required to be issued under the Stock Purchase Agreement, and fails to make such payment or payments or issue such shares within [***] days after receiving written notice of such
failure, MDACC may terminate this Agreement immediately upon written notice to Company. 
 (b)    Material
Breach. If either of MDACC or Company commits a material breach of its obligations under this Agreement or the Stock Purchase Agreement, except for breach as described in 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 20 

 
Section 15.2(a), and fails to cure that breach within [***] days after receiving written notice thereof, the non-breaching Party may terminate
this Agreement immediately upon written notice to the breaching Party, subject to completion of the dispute resolution process set forth in Article 16 and subsequent cure. Moreover, if BridgeBio commits a material breach of its obligations under any
agreement with the Company, including, but not limited to, the Series A PSPA, or if the Company breaches its obligations under the Series A PSPA, MDACC may terminate this Agreement immediately upon Written notice to Company. For purposes of this
Agreement, “Series A PSPA” means the Series A Preferred Stock Purchase Agreement dated March 3,2017 and entered into by and between Company and BridgeBio, notwithstanding any amendments or other modifications after such date. 

15.3    Effect of Expiration or Termination. 

(a)    All licenses and rights granted pursuant to this Agreement will terminate as of the effective date of termination.

 (b)    If the Agreement is terminated by either Party for any reason other than MDACC’s material breach of this
Agreement, then Company hereby agrees to assign and shall immediately assign all rights in Collaboration Technology to Board and shall execute such other documentation to memorialize such assignment as may be requested by Board. 

(c)    Each Party will promptly return all Confidential Information and Proprietary Materials of the other Party;
provided, that each Party may retain one (1) copy of the Confidential Information of the other Party in its archives solely for the purpose of establishing the contents thereof and ensuring compliance with its obligations hereunder. 

(d)    Upon the early termination of this Agreement, Company and its Affiliates and Sublicensees may complete and sell any
work-in-progress and inventory of Licensed Products that exist as of the effective date of termination, provided that (i) Company pays MDACC the applicable
running royalty or other amounts due on such sales of Licensed Products in accordance with the terms and conditions of this Agreement, and (ii) Company and its Affiliates and Sublicensees shall complete and sell all work-in-progress and
inventory of Licensed Products within [***] months after the effective date of termination. 
 (e)    In addition to the
assignment of Collaboration Technology set forth in Section 15.3(b), if the Agreement is terminated prior to the achievement of Proof of Concept, and Company terminates the Agreement other than pursuant to Section 15.2(b) for
MDACC’s material breach, Company agrees to discuss in good faith with MDACC the terms and conditions that Company may grant any necessary licenses under all other Company Technology to MDACC in order for MDACC to continue the Development of the
Licensed Products, either independently or in collaboration with one or more Third Parties; provided that, Company shall have no obligation to enter into any such license agreement with MDACC unless the Parties mutually agree on the terms and
conditions of such license agreement. 
 (f)    Expiration or termination of this Agreement for any reason shall not
relieve any Party of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration. 

15.4    Survival. The following provisions shall survive the expiration or termination of this Agreement: Article
1, Article 11, Article 12, Article 16 and Article 17, and Sections 7.1(f), 8.2 (but only with respect to obligation to provide final report and payment), 8.3, 12.4, 12.5, 14.1, 14.2, 15.3 and 15.4. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 21 

 ARTICLE 16 

DISPUTE RESOLUTION 

16.1    Mandatory Procedures. The Parties agree that any dispute arising out of or relating to this Agreement shall
be resolved solely by means of the procedures set forth in this Article 16, and that such procedures constitute legally binding obligations that are an essential provision of this Agreement. If either Party fails to observe the procedures of this
Article 16, as may be modified by their written agreement, the other Party may bring an action for specific performance of these procedures in any court of competent jurisdiction. Notwithstanding the foregoing or anything in this Agreement, the
provisions of this Article 16 as applied to Board and/or MDACC shall only apply to the extent authorized by the constitution and laws of the State of Texas, and shall not apply to Board or MDACC to the extent that such Party(ies) are not authorized
to participate in the Dispute Resolution procedures of this Article 16 pursuant to the constitution and laws of the State of Texas. 

16.2    Equitable Remedies. Although the procedures specified in this Article 16 are the sole and exclusive
procedures for the resolution of disputes arising out of or relating to this Agreement, either Party may seek a preliminary injunction or other provisional equitable relief if, in its reasonable judgment, such action is necessary to avoid
irreparable harm to itself or to preserve its rights under this Agreement. 
 16.3    Dispute Resolution
Procedures. Any controversy or claim arising out of or relating to this Agreement, or the breach thereof, shall be settled by binding confidential arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration
Association (“AAA”), and the procedures set forth below. In the event of any inconsistency between the Rules of AAA and the procedures set forth below, the procedures set forth below shall control. Judgment upon the award rendered by the
arbitrators may be enforced in any court having jurisdiction thereof. 
 (a)    The arbitration shall be conducted by a
panel of three neutral arbitrators who are independent and disinterested with respect to the Parties, this Agreement, and the outcome of the arbitration. Each Party shall appoint one neutral arbitrator, and these two arbitrators so selected by the
Parties shall then select the third arbitrator, and all arbitrators must have at least ten (10) years’ experience in mediating or arbitrating cases regarding the same or substantially similar subject matter as the dispute between MDACC and
Company. If one Party has given written notice to the other Party as to the identity of the arbitrator appointed by the Party, and the Party thereafter makes a written demand on the other Party to appoint its designated arbitrator within the next
[***] days, and the other Party fails to appoint its designated arbitrator within [***] days after receiving said written demand, then the arbitrator who has already been designated shall appoint the other two arbitrators. 

(b)    The arbitrators shall decide any disputes and shall control the process concerning these pre-hearing discovery matters. Pursuant to the Rules of AAA, the Parties may subpoena witnesses and documents for presentation at the hearing. 

(c)    Prompt resolution of any dispute is important to the Parties; and the Parties agree that the arbitration of any
dispute shall be conducted expeditiously. The arbitrators are instructed and directed to assume case management initiative and control over the arbitration process (including, without limitation, scheduling of events, pre-hearing discovery and
activities, and the conduct of the hearing), in order to complete the arbitration as expeditiously as is reasonably practical for obtaining a just resolution of the dispute. 

(d)    The arbitrators may grant any legal or equitable remedy or relief that the arbitrators deem just and equitable, to
the same extent that remedies or relief could be granted by a state 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 22 

 
or federal court, provided however, that no punitive damages may be awarded. No court action shall be maintained seeking punitive damages. The decision of any two (2) of the three
(3) arbitrators appointed shall be binding upon the Parties. Notwithstanding anything to the contrary in this Agreement, prior to or while an arbitration proceeding is pending, either Party has the right to seek and obtain injunctive and
other equitable relief from a court of competent jurisdiction to enforce that Party’s rights hereunder. 

(e)    The expenses of the arbitration, including, without limitation, the arbitrators’ fees, expert witness fees,
and attorney’s fees, may be awarded to the prevailing Party, in the discretion of the arbitrators, or may be apportioned between the Parties in any manner deemed appropriate by the arbitrators. Unless and until the arbitrators decide that one
Party is to pay for all (or a share) of such expenses, both Parties shall share equally in the payment of the arbitrators’ fees as and when billed by the arbitrators. 

(f)    Notwithstanding the foregoing, any disputes arising hereunder with respect to the inventorship, validity,
enforceability or other aspect of intellectual property rights shall be resolved by a court of competent jurisdiction and not by arbitration. 

(g)    Except as set forth below and as necessary to obtain or enforce a judgment upon any arbitration award, the Parties
shall keep confidential the fact of the arbitration, the dispute being arbitrated, and the decision of the arbitrators. Notwithstanding the foregoing, the Parties may disclose information about the arbitration to persons who have a need to know,
such as directors, trustees, management employees, witnesses, experts, investors, attorneys, lenders, insurers, actual or potential collaborators or corporate partners of Company, actual or potential acquirors of Company, and others who may be
directly affected provided that such persons are bound to keep such information confidential. Additionally, if a Party has stock which is publicly traded, the Party may make such disclosures as are required by applicable securities laws, but shall
use commercially reasonably efforts to seek confidential treatment for such disclosure. 
 16.4    Performance to
Continue. Each Party shall continue to perform its undisputed obligations under this Agreement pending final resolution of any dispute arising out of or relating to this Agreement; provided, however, that a Party may suspend performance of its
undisputed obligations during any period in which the other Party fails or refuses to perform its undisputed obligations. 

16.5    Statute of Limitations. The Parties agree that all applicable statutes of limitation and time-based
defenses (such as estoppel and laches) shall be tolled while the procedures set forth in Article 16 are pending. The Parties shall cooperate in taking any actions necessary to achieve this result. 

ARTICLE 17 

MISCELLANEOUS 

17.1    Notice. Any notice required by this Agreement shall be in writing and shall be deemed to have been
sufficiently given for all purposes thereof when sent by first class mail or reputable international courier (e.g., Federal Express or UPS) and shall be evidenced by the postmark at the point of mailing or by the dated delivery receipt of the
courier. All notices and any correspondence respecting this Agreement shall be transmitted as follows: 
 To Board/MDACC. if by mail:

 [***] 
 To Board/MDACC.
if by courier: 
 [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 23 

 To Company by mail or courier: 

PTP Pharmaceuticals, Inc. 
 [***]

 or other addresses as may be given from time to time under the terms of this notice provision. 

Communications (if any) regarding patent prosecution may be transmitted by electronic mail. For such communications to Board/MDACC sent via electronic mail,
the electronic mail shall be addressed or copied to [***]. 
 All notices under this Agreement shall be deemed effective upon receipt. A Party may change
its contact information immediately upon written notice to the other Party in the manner provided in this Section 17.1. 

17.2    Assignment and Successors. Neither this Agreement nor any obligation of a Party hereunder may be assigned
by any Party without the written consent of the other, which consent will not be unreasonably withheld, conditioned or delayed, provided, however, a Party may assign this Agreement and the rights, obligations and interests of such Party, in
whole but not in part, to any unrelated third party in connection with the arms-length transfer or sale to such third party of all or substantially all of the Party’s business “to which this Agreement relates, whether by merger, sale of
stock, sale of assets or otherwise. 
 17.3    Governing Law. This Agreement and all disputes
arising out of or related to this Agreement, or the performance, enforcement, breach or termination hereof, and any remedies relating thereto, shall be construed, governed, interpreted and applied in accordance with the laws of the State of Texas,
without regard to conflict of laws principles, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent shall have been granted. 

17.4    Force Majeure. No Party shall be responsible for delays resulting from causes beyond the reasonable control
of such Party, including, without limitation fire, explosion, flood, war, strike, or riot, provided that such Party uses Commercially Reasonable Efforts to avoid or remove such causes of nonperformance and continues performance under this Agreement
with reasonable dispatch whenever such causes are removed. 
 17.5    Amendment and Waiver. This Agreement may be
amended, supplemented, or otherwise modified only by means of a written instrument signed by the Parties. Any waiver of any rights or failure to act in a specific instance shall relate only to such instance and shall not be construed as an agreement
to waive any rights or fail to act in any other instance, whether or not similar. 
 17.6    Severability. In the
event that any provision of this Agreement shall be held invalid or unenforceable for any reason, such invalidity or unenforceability shall not affect any other provision of this Agreement, and the Parties shall negotiate in good faith to modify the
Agreement to preserve (to the extent possible) their original intent. If the Parties fail to reach a modified agreement within [***] days after the relevant provision is held invalid or unenforceable, then the dispute shall be resolved in accordance
with the procedures set forth in Article 16. While the dispute is pending resolution, this Agreement shall be construed as if such provision were deleted by agreement of the Parties. 

17.7    Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Parties and their
respective legal representatives, successors and assigns. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 24 

 17.8    Headings. All headings are for convenience only and shall
not affect the meaning of any provision of this Agreement. 
 17.9    Entire Agreement. This Agreement
constitutes the entire agreement between the Parties with respect to its subject matter and supersedes all prior agreements or understandings between the parties relating to its subject matter. 

17.10    Third Party Beneficiaries. No Person other than the Parties and their respective Affiliates and permitted
assignees hereunder shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement, except any Sublicensee who is party to a sublicense agreement that would survive in accordance with Section 2.2
shall be designated an intended third party beneficiary with respect to Section 2.2 and entitled to enforce its rights under Section 2.2 hereunder. 

17.11    Government Funding. Company understands that the subject matter of this Agreement may have been developed
under a funding agreement with the Government of the United States of America (“Government”) and, if so, that the Government may have certain rights relative thereto. This Agreement is explicitly made subject to the Government’s
rights under any such agreement and any applicable law or regulation. To the extent that there is a conflict between any such agreement, applicable law or regulation and this Agreement, the terms of such Government agreement, applicable law or
regulation shall prevail. 
 17.12    Privacy. Any data provided to Company that contains information acquired
from MDACC’s patients or study participants is intended to constitute fully de-identified data. MDACC shall ensure that all Protected Health Information (“PHI”) is de-identified in accordance with the standards set forth at 42 C.F.R 164.514. In the event PHI, as defined by the federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), as amended,
is inadvertently disclosed to Company by MDACC in connection with this Agreement, Company will immediately notify MDACC and will return or destroy such PHI, in accordance with MDACC’s instructions. Pending return or destruction of any PHI,
Company shall maintain the confidentiality of all information (including the PHI) and use reasonable efforts to prevent access to, use, or disclosure of the information (including the PHI). 

17.13    No Improper Inducement. Company, by execution hereof, acknowledges, covenants and agrees that Company has
not been induced in any way by Board, System, MDACC or employees thereof to enter into this Agreement, and further warrants and represents that (a) Company is entering into this Agreement voluntarily; (b) Company has conducted
sufficient due diligence with respect to all items and issues pertaining to this Agreement; and (c) Company has adequate knowledge and expertise, or has used knowledgeable and expert consultants, to adequately conduct such due diligence,
and agrees to accept all risks inherent herein. 
 17.14    Texas State Agency. MDACC is an agency of the State
of Texas and under the constitution and laws of the State of Texas possesses certain rights and privileges, is subject to certain limitations and restrictions, and only has such authority as is granted to it under the constitution and laws of the
State of Texas. Notwithstanding any provision hereof, nothing in this Agreement is intended to be, nor will it be construed to be, a waiver of the sovereign immunity of the State of Texas or a prospective waiver or restriction of any of the rights,
remedies, claims, and privileges of the State of Texas. Moreover, notwithstanding the generality or specificity of any provision hereof, the provisions of this Agreement as they pertain to MDACC are enforceable only to the extent authorized by the
constitution and laws of the State of Texas; accordingly, to the extent any provision hereof conflicts with the constitution or laws of the State of Texas or exceeds the right, power or authority of MDACC to agree to such provision, then that
provision will not be enforceable against MDACC or the State of Texas. 

  
 25 

 [remainder of this page intentionally left blank] 

  
 26 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized representatives. 
  

									
	THE UNIVERSITY OF TEXAS M. D.
ANDERSON CANCER CENTER	 		 	PTP PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Dan Fontaine
	 		 	By:	 	 /s/ Neil Kumar

	Name:	 	Dan Fontaine	 		 	Name:	 	Neil Kumar
	Title:	 	Executive VP, Administration	 		 	Title:	 	CEO
				
	THE BOARD OF REGENTS OF 
THE UNIVERSITY OF TEXAS SYSTEM	 		 		 	
					
	By:	 	 /s/ Dan Fontaine
	 		 		 	
	Name:	 	Dan Fontaine	 		 		 	
	Title:	 	Executive VP, Administration	 		 		 	

  
 27 

 EXHIBIT A 
  

							
	 MDACC Invention

Disclosure Report
No.
	  	Inventors	 	IDR Title	 	Licensed Patents
	 [***]
	  	[***]	 	[***]	 	[***]

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 28 

 EXHIBIT B 

INITIAL DEVELOPMENT PLAN 
 Objective:
[***] 
  

					
	 Activity
	  	Responsible	 	Timeline
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 29 

	[***]	 Certain information in this document has been omitted from this exhibit because it is both (i) not
material and (ii) would be competitively harmful if publicly disclosed. 

 AMENDMENT NO. 1 TO THE

 COLLABORATION AND LICENSE AGREEMENT 

This Amendment No. 1, effective this 10th day of July, 2017, to the Collaboration and License Agreement between the Parties dated March 3, 2017
(“Original Agreement”), is made by and among the Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, The
University of Texas M. D. Anderson Cancer Center (hereinafter “MDACC”), a member institution of System, and Navire Pharma, Inc., a Delaware corporation formerly known as PTP Pharmaceuticals, Inc. (“Company”). Board, MDACC, and
Company may herein be referred to collectively as the “Parties.” 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, the
sufficiency of which is hereby acknowledged, the Parties hereby agree to the following: 
 BACKGROUND 

 

	A.	 Board, MDACC, and PTP Pharmaceuticals, Inc. entered into the Original Agreement. 

 

	B.	 On or about April 26, 2017, PTP Pharmaceuticals, Inc. formerly changed its name to Navire Pharma, Inc.,
such that Navire Pharma, Inc. is now the legal name of the “Company” as that term is used in the Original Agreement 

  

	C.	 Board, MDACC, and Company desire to amend the Original Agreement. 

AMENDED TERMS 
  

	1.	 Exhibit A of the Original Agreement shall be deleted in its entirety and replaced with the form of Exhibit A
attached hereto. 

  

	2.	 The Parties acknowledge and agree that, except as set forth in this Amendment No. 1 to the Collaboration
and License Agreement, the terms and conditions of the Original Agreement shall remain in full force and effect. 

 IN WITNESS WHEREOF, the Parties hereto have caused their duly authorized representatives to execute this
Amendment No. 1 to the Collaboration and License Agreement. 
  

									
	BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM	 		 	NAVIRE PHARMA, INC.
					
	By:	 	 /s/ Christopher H. McKee
	 		 	By:	 	 /s/ Cameron Turtle

		 	Christopher H. McKee	 		 	Printed Name: Cameron Turtle
		 	Senior Vice President	 		 	Title: VP, BD & Ops
		 	The University of Texas	 		 	
		 	M. D. Anderson Cancer Center	 		 	
				
	 THE UNIVERSITY OF TEXAS

M. D. ANDERSON CANCER CENTER
	 		 		 	
					
	By:	 	 /s/ Ferran Prat
	 		 		 	
		 	 Ferran Prat, J.D., Ph.D.
 Senior Vice
President
 The University of Texas
 M. D. Anderson Cancer
Center
	 		 		 	

 EXHIBIT A 
  

							
	 MDACC Invention
 Disclosure
Report

No.                
         
	  	Inventors	  	IDR Title	  	Licensed Patents
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]